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NOTES
1. All the temperatures are expressed in degree centigrade (oC).
2. Melting points of all the compounds are uncorrected and have
been recorded by open capillary method.
3. Room temperature, wherever mentioned, normally corresponds
to 280 - 330C.
4. Silica gel-G was used for preparing the TLC plates using
different solvant systems.
5. Infra red spectra  of all the compounds were scanned on
SHIMADZU-FOURIER TRANSFORM INFRA RED (FTIR)-
8400 Spectrophotometer using KBr pellet method.
6. PMR Spectra were recorded on BRUKER Spectrophotometer
(300 MHz) using TMS as a internal standard and CDCI3, DMSO-d6
and TFA as solvants.
7. Electron Impact (EI)  mass spectra were recorded on GCMS-
QP2010 Mass Spectrometer. The matrix peaks may appear at
m/z 136,137,154,289,307 in the absence of any metal
ions  were not considered for mass fragmentations.
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“SYNTHESIS AND APPLICATION OF  SOME COMPOUNDS
OF  MEDICINAL INTEREST ’’
(A) Drug
The word drug is derived from the French word “drogue” which means
‘a dry herb’. It is the single active chemical entity present in a medicine that is
used for diagnosis, prevention, treatment/cure of a disease. This disease ori-
ented definition of drug does not include contraceptives or use of drugs for im-
provement of health. According to “WHO” a drug may be defined as “Any sub-
stance or product which is used or intended to be used for modifying or explor-
ing physiological system as pathological status for the benefit of the recipient”.
(B) Pharmacology
Pharmacology is the science of drugs. In a broad sense, it deals with inter-
action of exogenously administered chemical molecules (drugs) with living
system. It encompasses all aspects of knowledge about drugs, but most impor-
tantly those that are relevant to effective and safe use for medicinal purposes. For
thousands of years most drugs were crude natural products of unknown composi-
tion and limited efficiency. Only the over effects of these substances on the body
were rather imprecisely known, but how the same were produced was entirely
unknown. Over the past 100 years or so, drugs have been purified, chemically
characterized and a vast variety of highly potent and selective new drugs has been
developed. The two main divisions of pharmacology are pharmacodynamics and
pharmacokinetics.
(a) Pharmacodynamics :  It is derived from the Greek word “dynamic” means
power. What the drugs does to the body ? This includes physiological and
biochemical effects of drugs and their mechanism of action at macro-
molecular / sub cellular organ systems.
(b) Pharmacokinetics :  It is derived from the Greek word ‘Kinesis’ means
movement. What the body does to the drug ? This refers to movements of
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the drug in and alternation of the drug by the body; includes absorption,
distr ibut ion, binding /  local izat ion /  storage, biotransformation and
excretion of the drug.
Some other important aspects of pharmacology are given as under :
    * Pharmacotherapeut ics  :  I t  i s  the  app l ica t ion  o f  pharmacodyna -
mic  information together with knowledge of the disease for itspreven-
tion, mitigation or cure.
    * Clinical  Pharmacology  :  I t  is  the scient i f ic  study of  drug in man.
It  inc ludes pharmacodynamic and pharmacokinet ic  invest igat ion
i n healthy volunteers and in patients; evaluation of efficiency and safety
o f  d rugs  and  compara t i ve  t r ia l s  w i th  o ther  fo rms o f  t rea tments ;
surveillance of patterns of drug uses, adverse effects, etc.
    * Chemotherapy : It is the treatment of systemic infection / malignancy
with specific drugs that have selective toxicity for the infecting organism /
malignant cell with less effect on the host cells.
Drugs in general, can thus be divided into :
    * Pharmacodynamic agents : These are chemical substances designed
to have pharmacodynamic effect in the recipient.
    * Chemotherapeut ic  agents  :  These are chemical  substances de
signed for the treatment of infectious diseases or by the proliferation of
malignant cells.
(c) Essential Drug Concept: The ‘WHO’ has defined Essential Drugs as “those
 that satisfy the healthcare needs of majority of the population; they should there-
fore be available at all times in adequate amounts and in appropriate dosage form”.
It has been realized that only a handful of drugs out of the multitude
available can meet the health needs of majority of the people in any country, and
that may be well tested and cheaper drugs are equally (or more) efficient and safe
as their newer more expensive congeners. For optimum utilization of resources,
governments (specially in developing countries) should concentrate on these drugs
by identifying them as Essential Drugs. The “WHO” has laid down criteria guide
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selection of an essential drug :
(I) Adequate data on its eff iciency and safety should be available from
          clinical studies.
(II) It should be available in a form in which quality, including bioavailability,
and stability on storage can be assured.
(III) Its choice should depend upon pattern of prevalent diseases; availability
o f  fac i l i t ies  and t ra ined personnel ;  f inanc ia l  resources;  genet ic ,
demographic and environmental factors.
(IV) In case of two or more similar drugs, choice should be made on the basis
          of their relative efficiency, safety, quality, price, availability and cost
          benefit ratio should be a major consideration.
(V) Choice may also be influenced by comparative pharmacokinetic properties
and local facilities for manufacture and storage.
(VI) Most essential drug should be single compound. Fixed ratio combination
products should be included only when dosage of each ingredient meets
the requirements of a defined population group, and when the combination
has a proven advantage.
(VII) Selection of essential drug should be a continuous process which should
take into account the changing priorities for public health action, epide-
miological condition as well as availability of better drugs/ formulations and
progress in pharmacological knowledge.
(C)  Drug Development
Many natural products by trial and error, came into practise for combating
human ailments existent during early human observation. With the advent of
modern scientific approach, various plant medicines came under chemical
scrutiny, ultimately leading to the isolation of active principles since early.
Such compounds either in extract form or in pure form became a part of
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use for
over 5000 years for the treatment of various types of fever and respiratory
ailments, its active principle, Ephidrine was isolated in 1887. In 1925 chemical
investigations followed by pharmacological evaluation led this compound into the
modern medicine. Similarly during this period, urea stibamine was introduced as
the first drug in 1920 for the treatment of Kala-azar. In 1930, De Rauwolfia prepa-
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ration were first employed for sedative and hypotensive properties.
A drug is a substance having abnormal effect on certain body functions eg.
Strychnine stimulates the action of heart and aspirin retards its action. Since both
of them effects abnormally, the two substances are known as drugs. Chemical
sciences contributed extensively new discoveries leading to useful drugs since
after 1930. The modern concept of drug discovery started in 1933 by Gerhand
Domagk with his finding of “Prontosil Red” , a compound responsible for the
antibacterial activity. The advent of sulphonamides  drew the attention for the
different activities of various chemicals for bacterial and human cells, this impor-
tant factor prompted Florey and Chain in 1939 to investigate penicillin  which was
discovered ten years earlier by Alexander Fleming . The  spectacular chemothera-
peutical properties of penicillin and its dramatic war-time development for the treat-
ment of wounds made penicillin , a most commonly used inexpensive drug.
           A large number of important drugs have been introduced during the period
of 1940 to 1980. This period is known as “Golden period” of new drug discovery.
Thus starting from 1933 - the first antibacterial drug prontosil  leading to various
sulpha drugs ; 1940 – penicillin  ; 1945 – chloroquine  – antimalarial ; 1950 –
Methyldopa  – anti-hypertensive;  1967 – chlorothiazine -diuretic ; 1958 - adr-
energic beta blockers coronary vasodilatory; 1960 - semi synthetic penicillin  -
a n t i b a c t e r i a l ; 1 9 6 5 - t r i m e t h o p r i m - a n t i m i c r o b i a l ; 1 9 6 7 - d i s o d i u m
chromoglycoate -antiallergic; 1972 - cimetidine H2 – antagonist; 1975
-verapamil- calciumantagonist and 1981 - captopril  - antihypertensive. There are
some specific examples representing new therapeuticagent  eg. Metormine glipizide-
anti diabetic.
(D) Latest Drug Developments
The current interest in the creation of large, searchable libraries of organic
compounds has captured the imagination of organic chemists and the drug dis-
covery community. In numerous laboratories the Efforts are focused on the intro-
duction of chemical diversity, which have been recently reviewed and
pharmacologically interesting compounds have been identified from libraries of
widely different compositions.
Today, the chief source of agents for the cure, the mitigation or the
prevention of diseases are the organic compounds, natural or synthetic, together
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with so called organometallics. Such agents have their origin in a number of ways
(a) from naturally occurring materials of both plant and animal origin, and (b) from
the isolation of organic compounds synthesized in laboratory whose structures
are closely related to those of naturally occurring compounds for eg.atropine, ste-
roids, morphine, cocaine  etc. that have been known to possess useful medici-
nal properties.
The process of drug design is extensively driven by the instinct  and experi-
ence of pharmaceutical research scientists. It is often instructive to attempt to
“capture” these experiences by analyzing the historical record that are successful
drug design projects of the past. From this analysis, the inferences are drawn
which play an important role in shaping our  current and future projects. Towards
this region, we would like to analyse the structures of a large number of drugs - the
ultimate product of a successful drug design effort. Our goal for this is to  begin to
deconvolute this information in order to apply it to design of new drugs.
Different kinds of drugs are developed for different types of diseases viz.
which can be defined with their names of the modern drugs are as under.
(a) Anticancer drugs
The drugs, which stops the abnormal growth of cell tissues in human body,
are termed as anticancer drug. Vinblastin and Busulphan are the novel
anticancer drugs.
(b) Hepatoprotective drugs
Drugs, which gives vitality to liver and protects liver by giving immunity power
against antibodies, are termed as Hepatoprotective drug.
(c) Antimalarial drugs
Drugs, which kills the plasmodium causing malaria are called antimalarial
drug. Combination of Sulphamethoxazole  with Pyrimethamine is a novel
antimalarial drug.
(d)      Drug for meningitis
Drugs, which cures the inflammation of meningit is, are termed as
meningitis drugs Cifalexin  is a novel meningitis drug.
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(e)      Drug for typhoid
Drugs, which kills the bacteria of Salmonella typhi causing typhoid are known
as typhoid drugs. A novel drug for typhoid is Ciprofloxacin .
(f)       Antidiabetic drugs
Drugs, which converts the excess glucose of blood into glycogen are termed
as antidiabetic drugs. Novel antidiabetic drugs are Metformin, Glipizide and
Gliclazide.
(g) Antitubercular drugs
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus cures
lesions of pleural cavity. A novel antitubercular drug is Ethambutol.
(h) Antiasthamatic drugs
             Drugs, which prevents the attack of asthama and gives relax respiration
are called antiasthamatic drugs. Novel antiasthamatic drugs are Ethophylline,
Theophylline and Asmon.
(i) Antihypertensive drugs
            Drugs, which normalizes the blood pressure by dilating blood vessels are
called antihypertensive drugs. Novel antihypertensive drugs are Atenolol,
Amlodipine  and Nifedipine.
(j)        Anti-AIDS drugs
          Drugs, which kills the viruses of AIDS i.e., HIV-1 and HIV-2 are called
anti-AIDS drugs. Novel drugs are Zidovudine, Acyclovir  and Didanosine .
(k) Antacid drugs
           Drugs, which neutralize the acid in stomach and stops excessive secretion
of acid, are called antacid drugs. Novel antacid drugs are Omeprazole  and
Lansoprazole.
(l)      Non steroidal antiinflammatory drugs (NSAID)
Drugs, which gives relief from fever, pain and inflammation are called NSAID.
Novel NSAID are Pyroxicam , Meloxicam  and Nimesulide.
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Different kind of drugs generally used are designed as anaesthetic,
antituberculostatic, antihypertensive, anticonvulsant, anthelmintic, antiinflamma-
tory, sedative and hypnotics which prompted us to synthesise drugs having
benzo[b]thiophene, pyrimidine, 4-pyrimidinyl sulphonamide, 1,4-dihy-
dropyridine and  pyrido[2,3-d;6,5-d’]dipyrimidine  moieties as a better thera-
peutic activity.
Aims and objectives of the present investigation are
(a) To generate several biologically active moieties such as benzo[b]thio-
phene, pyrimidine, 4-pyrimidinyl sulphonamide, 1,4-dihydropyridine
and  pyrido[2,3-d;6,5-d’]dipyrimidine .
(b) To characterize these products for their structural assignment using vari-
ous spectroscopic techniques like IR, PMR and Mass spectroscopy.
(c) To screen these new derivatives for their antimicrobial activity using  diff-
erent stra ins of  bacter ia and fungi i  and to  compare ant imicrob ia l
act iv i ty with different known drugs at different concentrations for their MIC
values.
In view of these facts, the research work presented in thesis are as follows.
( A ) STUDIES ON  BENZO[b]THIOPHENES
( B ) STUDIES ON PYRIMIDINES
(a) STUDIES ON PYRIMIDINES
(b) STUDIES ON 4-PYRIMIDINYLSULPHONAMIDES
( C ) STUDIES ON 1,4-DIHYDROPYRIDINES
( D ) STUDIES ON PYRIDO[2,3-d;6,5-d’]DIPYRIMIDINES




Thiophene ring fused with benzen nucleus is known as benzo[b]thiophene.




Benzo[b]thiophene was isolated and purified from crud petroleum and coal
by F. P. Richter et.al1.
APPLICATIONS OF BENZO[b]THIOPHENES
S. Bruno et.al.2, have suggested as wood preservative, F. M. Roberts et.al.3,
have described its utility in metal complex dyes. C. W. Hargis et.al.4, reported
plant growth regulator activity higher intrinstic activity in rat stomach fandus have
been studied by C. W. Jerrold  et.al.5, of benzo[b ]thiophene derivatives.
D. David et.al.6, have compared the chemotherapeutic activity against fusarium
wilt of tomatoes of thiophenes, benzo[b]thiophenes and dibenzothiophenes .
SYNTHETIC METHODS OF BENZO[b]THIOPHENES
Benzo[b]thiophenes  have been synthesized by the following routes.
(1) Action of cuprous cyanide followed by heating with diazophenyl thioglycol-
icacid7.
(2) By cyclization of 2-bromomethyl malonic ester  with sodium salt of m-bro-
mothiophenol in polyphosphoric acid 8.
(3) By the reaction of phenyl acetylene / styrene / phenyl ethyl marcaptan
/ 2-phenyl-2-marcapto ethane / acetophenone  with H2S using Cr2O3
Catalyst at 550°C9.
(4) By cyclization of brominated 2-methylthio-b -acetostyrene in pyridine10.
(5) By cyclo condensation of malononitrile  and sulfur with cyclohexathion
in basic catalyst yielded 2-amino-3-cyanobenzo[b]thiophene11.
(6) By the chemoselective heterocyclization of ketones and aldehydes with
active methylene compounds having nitriles and sulfur in presence of mor-
(1) (2)
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pholine or diethylamine12.
(7) By cyclization of o-nitrobenzaldihyde  and methylthioglycolate13.
(8) In 1906 P. Friedlander14et.al, have prepared 2-amino-3-carboxybenzo-
[b]thiophene  by the action of cuprous cyanide  (sandmayer reaction) on
diazotized  o-aminothiophenol followed by cycloaddition with chloroacetic
acid .
(9) By the reaction of cinnamic acid  with SOCl2 using pyridine as catalyst at
98°C15.





























THERAPEUTIC IMPORTANCE OF BENZO[b]THIOPHENES
Over recent years there has been an increasing interest in the chemistry of
benzo[b]thiophene because of their biological significance. B eside the currently
established drugs Sertaconazole , Raloxifene and Zileuten. Benzo[b]thiophene
derivatives are associated with diverse biological activities viz.
(a) Analgesic 16-18 (b) Antitubercular19
(c) Antiallergic20-22 (d) Antibacterial23-25
(e) Anticonvulsant26-27 (f) Antifungal28-29
(g) Antihistaminic 30 (h) Antiinflammatory31-33
(i) Antitumor34-35 (j) Antiviral36-37
(k) b -Adrenergic 38-39 (l) Diuretic40-42
(m) Hypoglycemic43 (n) Insecticidal44-47
(o) Neumatocide48 (p) Neuroleptic 49
(q) Anticancer50-53
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C. Routledge et.al.54, have prepared benzo[b]thiophene (3) derivatives and










D. J. Sall et.al.55, have prepared diamino benzo[b]thiophene (4) deriva-







X = CH, N
Kuanuniamine A  (5) is the simplest member of a group of marine alka-
loids which show strong antitumor activity in vivo and  in vitro. They also
exhibit immunosuppressive and antiviral properties . W.F. Reynolds et.al.56,












A. Monge et.al.57, have prepared benzo[b]thiophene (7) derivatives and re-






R  =  H, F
Ar1= 1-Naphthyl, 2-Quinolyl,
         3-Quinolyl, 4-Quinolyl,
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J. A. Valderrama et.al.58, have prepared benzo[b]thiophenes (8,9) and
their application of benzo[b]thiophenequinones and naphthothiophenequinones
with ortho-amino functional on the thiophene ring possess a variety of biological










3  R = H
4  R = Ac
1  R = NAc2
2  R = NHAc
S. Brian et.al.59, have prepared 3-benzylbenzo[b]thiophenes (10)  which
are useful for treating diseases associated with post-menopausal syndrome ,







R6 R1 = OH, OCO(alkyl), OCO(aryl)
R
2











R4 ,R5 = CO(CH2)2Me, CO(CH2)3Me, alkyl
R
6





M. B. Sporn et.al.60, have synthesized benzo[b]thiophenes (11)  derivative





S. Yous et.al.61, have synthesized and evaluated four novel benzo[b]thio-
phenes (12)  derivatives desined as Serotonin N-acetyltransferase (AANAT)
inhibitors . Specific AANAT inhibitors could be useful for treatment of different
physiopathological disorders encountered in diseases such as seasonal




















H. Lee et.al.62, have synthesized benzo[b]thiophenes (13) derivatives
and evaluated for the NHE-1 inhibitory activity and cardioprotective efficacy







K.Z. Grace et.al.63, have synthesized benzo[b]thieno[2,3-c]quinolones
(14,15)  and evalua ted antiproliferative effect on a series of human tumor cells






R1 = H, CH3, OCH3, COOCH3, 
        Br, CN 
          
R  = H, CH3, OCH3, COOCH3, F, NO2, 





W. W. WardakhanIn et.al.64, have synthesized 2-aminothiophene-3-
carboxamide (16)  derivatives and evaluated for it’s antimicrobial activity against













In view of procuring highly potent biodynamic agents and after reviewing
literature survey on benzo[b]thiophenes  for their various methods of synthesis
and different biological activities, synthesis of benzo[b]thiophene  have been
undertaken which can be summerized in the following sections as under.
SECTION - I : PREPARATION AND BIOLOGICAL SCREENING OF SUBSTI-
TUTED-3-CHLORO-1-BENZO[b]THIOPHENE-2-CARBONYL-
CHLORIDES.
SECTION - II :    PREPARATION AND BIOLOGICAL SCREENING OF SUBSTI-
TUTED-3-CHLORO-1-BENZO[b]THIOPHENE-2-CARBOXYL-
ICACIDS .
SECTION - III :    PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITU-
       TED-3-CHLORO-1-BENZO[b]THIOPHENE-2-CARBOXAMIDES.
SECTION - IV :  PREPARATION AND BIOLOGICAL SCREENING OF SUBSTI-
      TUTED-3-CHLORO-N-ISOPROPYL-1-BENZO[b]THIOPHENE-2-
      CARBOXAMIDES.
SECTION - V :   PREPARATION AND BIOLOGICAL SCREENING OF SUB-
      STITUTED-3-CHLOROBENZO[b]THIOPHEN-2-YL)(MORPHO-
      LIN-1’-YL)METHANONES .
SECTION - VI :  PREPARATION AND BIOLOGICAL SCREENING OF SUB-
      STITUTED-(3-CHLOROBENZO[b]THIOPHEN-2-YL)(4’-PHE-
      NYLPIPERAZIN-1’-YL)METHANONES .
(16)
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SECTION - I
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-
3-CHLORO-1-BENZO[b]THIOPHENE-2-CARBONYLCHLORIDES .
Due to various biodynamic activities16-53  of benzo[b]thiophene  and with
a view to have potent therapeutic agents, the synthesis of substituted-3-chloro-
1-benzo[b]thiophene-2-carbonylchlorides  (a1-8) have been undertaken by the
cyclocondensation of substituted cinnamic acid s and thionyl chloride  in the pres-






The constitution of the products (a1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (a1-8) were assayed for their in vitro biological assay like
antibacterial activity  towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram negative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 at different concentrations (µg/ml) : 0 (control), 5, 10, 25,
50, 100, 200, 500. The biological activit ies of the synthesized compounds
were compared with standard drugs viz. Ampicillin , Chloramphenicol, Cipro-
floxacin, Norfloxacin  (antibacterial) and Griseofulvin (antifungal).
(a1-8)             R=Aryl
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Internal Standard : TMS ; Solvent : CDCl3, DMSO; Instrument : BRUKER Spectrometer
(300 MHz)

































































































m/z = 211 (M+1)
m/z = 134 (M -2)
m/z = 168.5 (M+1)
m/z = 124 (M -1)
m/z = 92 (M+1)
m/z = 230 (M+2)
m/z = 84(M -1)
m/z = 100 (M+1)
m/z = 106
m/z = 88
m/z = 196.5 (M-1) (BP)
(a1)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-3-
CHLORO-1-BENZO[b]THIOPHENE-2-CARBONYL CHLORIDES .
(A) Preparation of 3-chloro-1-benzo[b]thiophene-2-carbonylchloride
(a1).
A mixture of cinnamic acid  (14.8 gm, 0.1 M), thionyl chloride (30 ml) and
pyridine (1ml)  was heated at 98°C for 24 hrs. Then the excess of thionyl chlo-
ride was distilled off at 98°C for 12 hrs. The content was poured into hot dioxane .
The yellow crystalline product  so obtained  was recrystallized from dioxane . Yield
: 75%, M.P. : 105°C, Rf
1
 : 0.41, Rf
2
 : 0.53 (Required :  C: 46.75%; H: 1.73%; S:
13.85% for C9H4OSCl2, Found : C:46.70%; H: 1.69%; S: 13.81% ).
Similarly, other compounds  (a1-8) were synthesized. The physical data
are recorded in Table No. 1 .
(B) Antimicrobial activity of substituted-3-chloro-1-benzo[b]thiophene-
2-carbonylchlorides (a1-8).
Antimicrobial activity testing was carried out by using cup-plate method65,
which has been described as under.
     * Antibacterial activity
S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTCC-441
(Gram positive bacteria) were grown in nutrient broth and E. coli MTCC-443 (Gram
negative bacteria) in Peptone water (PW, 1% bacteriological peptone and 0.5% NaCl)
for 24 hrs., this gave an optimum growth of the test  bacteria. Each purified compound
was dissolved in dimethyl formamide (DMF) sterilized by filtration by using sintered
glass filter and stored at 4°C. Each agent was then added to molten nutrient agar in
the following concentrations (µg/ml) : 0 (control), 5, 10, 25,50, 100, 200, 500
and poured into sterile petridished. The pH of the media was maintained at 7.2
Studies on benzo[b]thiophenes... 34
to7.4. The inoculum consisted of an overnight grown broth culture of a
bacteriumdiluted in such a manner that a 2 mm (internal diameter) loopful of the
culture contain 105 colony-forming unit (CFU). These were then spot inoculated
on nutrient  agar  plates containing increasing amount of a compound, incubated
at 37°C up to 24 hrs. for determination of the minimum inhibitory concentra-
tion66-67  (MIC). Which are recorded in zones of inhibition in mm for bacteria.
    * Antifungal activity
C. albicans  MTCC-227 and A. niger MTCC-282  was employed for testing
antifungal activity using cup-plate method. The culture was maintained on
Sabouraud's agar for 72 hrs., this gave an optimum growth of the test fungal spores.
Each purified compound was dissolved in dimethyl formamide  (DMF)  sterilized
by filtration by using sintered glass filter and stored. Each agent was then added
to Sabouraud's agar in the following concentrations (µg/ml):  0 (control), 5,
10, 25, 50, 100, 200, 500  and poured into sterile petridished. The inoculum con-
sisted of an overnight grown broth culture of a bacterium diluted in such a manner
than a 2 mm (internal diameter) loopful of the culture contain 105 colony-forming
unit (CFU). These were then spot inoculated on Sabouraud's agar plates contain-
ing increasing amount of a compound, incubated at 37°C up to 48 hrs. for deter-
mination of the minimum inhibitory concentration (MIC)66-67. The zones of
inhibition in mm of test solutions are recorded in Table No. 1a, 1b & 1c  .  Which
are recorded in zones of inhibition in mm for fungii.
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SECTION - II
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-
3-CHLORO-1-BENZO[b]THIOPHENE-2-CARBOXYLICACIDS .
Due to various biodynamic activities16-53  of benzo[b]thiophene  and with
a view to have potent therapeutic agents, the synthesis of substituted-3-chloro-
1-benzo[b]thiophene-2-carboxylicacids  (b1-8) have been undertaken by the
condensation of substituted 3-chloro-1-benzo[b]thiophene-2-carbonylchl-






The constitution of the products (b1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (b1-8) were assayed for their in vitro biological assay like
antibacterial activity  towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram negative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 at different concentrations (µg/ml) : 0 (control), 5, 10, 25,
50, 100, 200, 500. The biological activit ies of the synthesized compounds
were compared wi th standard drugs viz. Ampicillin, Chloramphenicol,
Ciprofloxacin, Norfloxacin  (antibacterial) and Griseofulvin (antifungal).
(b1-8)                 R=Aryl
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   Internal Standard : TMS ; Solvent : CDCl3, DMSO; Instrument : BRUKER Spectrom-
   eter (300 MHz)


































































































m/z = 196.5 (M+2)
m/z = 134 (M-1)
m/z = 168.5 (M-1)
m/z = 148 (M-2)
m/z = 106 (M -2)
m/z = 114 (M+1)
m/z = 212.5 (M+2)
m/z = 138 (M+1)
m/z = 98
m/z = 124 (M-2)
m/z = 162 (M-2)
m/z = 184.5 (M+2)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-
3-CHLORO-1-BENZO[b]THIOPHENE-2-CARBOXYLIC ACIDS .
(A) Preparation of substituted-3-chloro-1-benzo[b]thiophene-2-carbo-
nylchlorides (a1).
For preparation refer Part-I, Section-I, Page No. 33.
(B) Preparation of 3-chloro-1-benzo[b]thiophene-2-carboxylicacid  (b1).
A mixture of 3- chloro-1-benzo[b] thiophene-2-ca rbony lchloride
(2.31gm, 0.01 M) and aq. NaOH  (0.40 gm, 0.01 M) in dioxane  (25 ml) was heated
under refluxed condition for 3 hrs. Then the reaction mixture was kept at  room
temperature for 2 hrs. The white crystalline product  so obtained  was isolated and
recrystallized from dioxane . Yield : 56%, M.P. : 148°C, Rf
1
 : 0.54, Rf
2
 : 0.62 (Re-
quired :  C: 50.82%; H: 2.35%; S: 15.06% for C9H5O2SCl, Found : C: 50.78%; H:
2.30%; S:15.01% ).
Similarly, other compounds  (b1-8) were synthesized. The physical data
are recorded in Table No. 2 .
(C) Antimicrobial activity of substituted-3-chloro-1-benzo[b]thiophene-
2-carboxylicacids (b1-8).
Antimicrobial activity testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table
No. 2a, 2b & 2c.
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SECTION - III
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-
3-CHLORO-1-BENZO[b]THIOPHENE-2-CARBOXAMIDES .
Due to various biodynamic activities16-53  of benzo[b]thiophene  and with
a view to have potent therapeutic agents, the synthesis of substituted-3-chloro-
1-benzo[b]thiophene-2-carboxamides  (c1-8) have been undertaken by the
condensation of substituted 3-chloro-1-benzo[b]thiophene-2-carbonylchlo-






The constitution of the products (c1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (c1-8) were assayed for their in vitro biological assay like
antibacterial activity  towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram negative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 at different concentrations (µg/ml) : 0 (control), 5, 10, 25,
50, 100, 200, 500. The biological activit ies of the synthesized compounds
were compared wi th standard drugs viz. Ampicillin, Chloramphenicol,
Ciprofloxacin, Norfloxacin  (antibacterial) and Griseofulvin  (antifungal).
(c1-8)        R=Aryl
Studies on benzo[b]thiophenes... 51
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    Internal Standard : TMS ; Solvent : CHCl3, Acetone; Instrument : BRUKER Spectrometer
    (300 MHz)























































































m/z = 134 (M-2)
m/z = 100 (M-2)
m/z = 168.5
m/z = 84 (M+2)
m/z = 211.5 (M+2)
m/z = 92 (M+1)
m/z = 88 (M+1)
m/z = 196.5 (M-1)
m/z = 106 (M+1)
m/z = 124 (M-1)
(BP)
(c1)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-
3-CHLORO-1-BENZO[b]THIOPHENE-2-CARBOXAMIDES .
(A) Preparation of 3-chloro-1-benzo[b]thiophene-2-carbonylchloride (a1).
For preparation refer Part-I, Section-I, Page No. 33.
(B) Preparation of 3-chloro-1-benzo[b]thiophene-2-carboxamide (c1).
A mixture of 3-chloro-1-benzo[b ] thiophene-2- c a r b o n y lchloride
(2.31gm, 0.01 M) and ammonia (2 ml) in dioxane (25 ml) was heated under
refluxed condition for 3 hrs. Then the reaction mixture was kept at room tempera-
ture for 2 hrs. The white crystalline product  so obtained  was isolated and recrys-
tallized from dioxane . Yield : 50%, M.P. : 156°C, Rf
1
 : 0.63, Rf
2
 : 0.72 (Required :
C: 51.06%; H: 2.84%; N: 6.62% for C9H6NOSCl, Found : C: 51.01%; H: 2.80%;   N:
6.59% ).
Similarly, other compounds  (c1-8) were synthesized. The physical data
are recorded in Table No. 3.
(C) Antimicrobial activity of substituted-3-chloro-1-benzo[b]thiophe-
ne-2-carboxamides (c1-8).
Antimicrobial activity testing was carried out as described in part-I, sec-
tion-I, page No. 33. The zone of inhibition of test solution are recorded in Table
No. 3a, 3b & 3c .
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SECTION - IV
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-
3-CHLORO-N-ISOPROPYL-1-BENZO[b]THIOPHENE-2-CARBOXAMIDES.
Due to varous biodynamic activities16-53 of benzo[b]thiophene  and with
a view to have potent therapeutic agents, the synthesis of substituted-3-chloro-
N-isopropyl-1-benzo[b]thiophene-2-carboxamides  (d1-8) have been under-
taken by the condensation of substituted 3-chloro-1-benzo[b]thiophene-2-








The constitution of the products (d1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (d1-8) were assayed for their in vitro biological assay like
antibacterial activity  towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram negative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 at different concentrations (µg/ml) : 0 (control), 5, 10, 25,
50, 100, 200, 500. The biological activit ies of the synthesized compounds
were compared wi th  s tandard drugs viz. Ampicillin, Chloramphenicol,
Ciprofloxacin, Norfloxacin  (antibacterial) and Griseofulvin (antifungal).
(d1-8)           R=Aryl
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 Internal Standard : TMS ; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer(300 MHz)





































































































m/z = 106 m/z = 124 (M-1)
m/z = 92
m/z = 134 (M-2)
m/z = 77 m/z = 168.5
m/z = 196.5(M-1) (BP)m/z = 211.5
m/z = 253.5 (M+1)
(d1)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-3-
CHLORO-N-ISOPROPYL-1-BENZO[b]THIOPHENE-2-CARBOXAMIDES.
(A) Preparation of 3-chloro-1-benzo[b]thiophene-2-carbonylchlorides
(a1).
For preparation refer Part-I, Section-I, Page No. 33.
(B) Preparation of 3-chloro-N-isopropyl-1-b enzo[b]thiophene-2-carbo-
xamide (d1).
A mixture of 3-chloro-1-benzo[b ]thiophene-2-ca rbony lchloride
(2.31gm, 0.01 M), isopropyl amine  (0.59 ml, 0.01 M) and pyridine (2-3 drops)
in dioxane (25 ml) was heated under refluxed condition for 4 hrs. Then the reac-
tion mixture was poured into crushed ice. The white product so obtained was iso-
lated and recrystallized from dioxane . Yield : 58%, M.P. : 167°C, Rf
1
 : 0.44, Rf
2
 :
0.53 (Required :  C: 56.80%; H: 4.73%; N: 5.52% for C12H12NOSCl, Found : C:
56.75%; H: 4.69%; N: 5.50% ).
Similarly, other compounds (d1-8) were synthesized. The physical data are
recorded in Table No. 4 .
(C) Antimicrobial activity of substituted-3-chloro-N-isopropyl-1-benzo[b]-
thiophene-2-carboxamides (d1-8).
Antimicrobial activity testing was carried out as described in part-I, sec-
tion-I, page No. 33. The zone of inhibition of test solution are recorded in Table
No. 4a, 4b & 4c .





































































   
































































































































































































































































































































































   
   







   
   














































































































































































































































































































































































































































   





























































































































































































































































































































































































































































































































































































































































































































   
















































































































































































































































































































































































































































































































































































































































































































































   































































































































































































































































































































Studies on benzo[b]thiophenes... 72
SECTION - V
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-
3-CHLOROBENZO[b]THIOPHEN-2-YL)(MORPHOLIN-1’-YL)METHANONES .
Due to various biodynamic  activities16-53 of benzo[b]thiophene  and
with a view to have potent therapeutic agents, the synthesis of substituted-(3-
chlorobenzo[b]thiophen-2-yl)(morpholin-1’-yl)methanones (e1-8) have been
undertaken by the condensation of substituted-3-chloro-1-benzo[b]thio-







The constitution of the products (e1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (e1-8) were assayed for their in vitro biological assay like
antibacterial activity  towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subti l l is MTCC-441 (Gram posit ive) and E. col i  MTCC-443  (Gram
negative) bacterial strain and antifungal activity  towards A. niger  MTCC-282
and C. albicans  MTCC-227 at different concentrations (µg/ml) : 0 (control), 5, 10,
25, 50, 100, 200, 500. The biological activit ies of the synthesized compounds
were compared wi th  s tandard drugs viz. Ampicillin , Chloramphenicol,
Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(e1-8)        R=Aryl
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Internal Standard : TMS ; Solvent ; DMSO ; Instrument : BRUKER Spectrometer (300 MHz)





























































































































m/z = 219 (M-1)
m/z = 162 (M-1)
m/z = 168.5
m/z = 146.5(M+1)
m/z = 281.5 (M+1)
m/z = 134 (M-2)m/z = 124 (M
-1)
m/z = 110(M-2)
m/z = 205 (M-1)
m/z = 87
m/z = 86
m/z = 196.5 (M-1)(BP)
(e1)
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-
3-CHLOROBENZO[b]THIOPHEN-2-YL)(MORPHOLIN-1’-YL)METHANONES .
(A) Preparation of 3-chloro-1-benzo[b]thiophene-2-carbonylchlorides
(a1).
For preparation refer Part-I, Section-I, Page No. 33.
(B) Preparation of 3-chlorobenzo[b]thiophen-2-yl)(morpholin-1’-yl)-
methanone  (e1).
A mixture of 3-chloro-1-benzo[b ]thiophene-2-ca rbony lchloride
(2.31gm, 0.01 M) and morpholine (0.87ml, 0.01 M) in dioxane (25 ml) was heated
under refluxed condition for 3 hrs. Then the reaction mixture was kept at room
temperature for 2 hrs. The white crystalline product  so obtained  was isolated
and recrystallized from dioxane . Yield :65%, M.P. : 134°C, Rf
1
 : 0.36, Rf
2
 : 0.49
(Required :  C: 55.42%; H: 4.26%; N: 4.97% for C13H12NO2SCl, Found : C:
55.37%; H: 4.21%; N: 4.95% ).
Similarly, other compounds  (e1-8) were synthesized. The physical data
are recorded in Table No. 5.
(C) Antimicrobial activity of substituted-3-chlorobenzo[b]thiophen-2-
yl)(morpholin-1’-yl)methanones (e1-8).
Antimicrobial activity testing was carried out as described in part-I, sec-
tion-I, page No. 33. The zone of inhibition of test solution are recorded in Table
No.5a, 5b & 5c .
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SECTION - VI
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-
(3-CHLOROBENZO[b]THIOPHEN-2-YL)(4’-PHENYLPIPERAZIN-1’-YL)METH-
ANONES .
Due to various biodynamic activities16-53  of benzo[b]thiophene  and with
a view to have potent therapeutic agents, the synthesis of substituted-(3-
chlorobenzo[b]thiophen-2-yl)(4’-phenylpiperazin-1’-yl)methanones (f1-8 )
have been undertaken by the condensation of substituted 3-chloro-1-benzo-








The constitution of the products (f1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (f1-8) were assayed for their in vitro biological assay like
antibacterial activity  towards S. pyogens MTCC-442 ,S. aureus MTCC-96  and
B. subtil l is MTCC-441  (Gram posit ive) and E. col i  MTCC-443  (Gram
negative) bacterial strain and antifungal activity  towards A. niger  MTCC-282
and C. albicans  MTCC-227 at different concentrations (µg/ml) : 0 (control), 5, 10,
25, 50, 100, 200, 500. The biological activit ies of the synthesized compounds
were compared wi th  s tandard drugs viz. Ampicillin , Chloramphenicol,
Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(f1-8)               R=Aryl
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   Internal Standard : TMS ; Solvent : CDCl3, DMSO ; Instrument : BRUKER Spectrometer
   (300 MHz)




























































































































m/z = 182.5 (M-1)
m/z = 168.5 (M-1)m/z = 134 (M-2) (BP)
m/z = 92 (M-1)
m/z = 106 (M-2)
m/z = 77
m/z = 356.5 (M+2)
S
O
m/z = 161 (M-2)
+
m/z = 124 (M-2)
(f1)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-
(3-CHLOROBENZO[b ]THIOPHEN-2-YL)(4’-PHENYLPIPERAZIN-1’-YL)
METHANONES .
(A) Preparation of 3-chloro-1-benzo[b]thiophene-2-carbonylchloride
(a1).
For preparation refer Part-I, Section-I, Page No. 33.
(B) Preparation of (3-chlorobenzo[b]thiophen-2-yl)(4’-phenylpiperazin-
1’-methanone (f1).
A mixture of 3-chloro-1-benzo[b ]thiophene-2-ca rbony lchloride
(2.31gm, 0.01 M), N-phenylpiperazine  (1.62ml, 0.01 M) and pyridine (2-3 drops)
in dioxane (25 ml) was heated under refluxed condition for 3 hrs. Then the reac-
tion mixture was poured into crushed ice. The white product  so obtained  was
isolated and recrystallized from dioxane . Yield : 58%, M.P. : 148°C, R f
1
 : 0.55, R f
2
: 0.63 (Required :C: 63.95%; H: 4.77%; N: 7.85% for C19H17N2OSCl, Found : C:
63.91%; H: 4.73%; N: 7.82% ).
Similarly, other compounds  (f1-8) were synthesized. The physical data
are recorded in Table No.6 .
(C) Antimicrobial activity of substituted-(3-chlorobenzo[b]thiophen-2-
yl)(4’-phenylpiperazin-1’-methanones (f1-8).
Antimicrobial activity testing was carried out as described in part-I, sec-
tion-I, page No. 33. The zones of inhibition of test solution are recorded in Table
No. 6a, 6b & 6c .
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Pyrimidine  (17) is a six membered heterocyclic compound consisting of
two nitrogen atoms at 1 and 3 positions of heterocyclic ring.
Generally pyrimidine derivatives such as 2-hydroxy-substituted-pyrimidine,
2-mercapto-substituted-pyrimidine and  2-amino-substituted-pyrimidine  are
studied. Pyrimidines have been isolated from the nucleic acid  hydrolysates.
Pyrimidines are among those molecules that make life possible, have
been some of the building blocks of DNA and RNA. Several analogues of
pyrimidines have been used as compounds that interfere with the synthesis and
functioning of nucleic acids e.g. fluorouracil, which has been used in cancer
treatment. Also there are some thiouracil derivatives, which produce adverse
reduction in susceptible patients and found more potent and less likely to produce
side effects and is being widely used68. There are several other important groups
of pyrimidines with medicinal uses.
Pyrimidine ring carrying various substituents may be built up from two or
three aliphatic fragments by the principle synthesis or by a variety of other  synthe-
ses, which are complimentary rather than alternative to it. An alternative method of
synthesis is the isomerisation or break down of another heterocycles such as
hydration of purine, but such methods are rarely used. Pyrimidine is best  consid-
ered as a resonance hybrid to which the uncharged equivalent Kekule structures
18 and 18a and charged structures 18b and 18g contributes. The self consistent p
(pi) electron densities required for the ground state of pyrimidine are 0.776, 0.825
and 1.103 for positions 2, 4 and 5 respectively69. Despite considerable localization
of p (pi) electrons at nitrogen atoms of pyrimidines the ring system is still suffi-
N
N
   pyrimidine
(17)
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ciently aromatic to possess substantial stability. This has a great advantage in the























The first primary synthesis from aliphatic fragments was carried out by
Frankland et.al., in 1848. Since then a many distinct primary synthetic methods
have been devised70-79.  It is also possible to prepare pyrimidines from other
heterocyclic compounds such as pyrrole80, imidazole81 , isoxazole and
oxazole 82-83, pyridine84, pyrazine85, 1,3,5-triazine86, oxazine87, thiaz-
ine88 by different processes.
SYNTHETIC METHODS FOR PYRIMIDINES
Various methods for synthesis of pyrimidines  which are reported in the
literature are as follows.
(a) By the condensation of urea and malonic acid led to formation of pyrimidine89.
(b) By the condensation of malonic ester and urea led to formation of pyrimidine90.
(c) By the condensation of formamidine with phenylazomalononitrile led to
formation of 4,5,6-triaminopyrimidine91.
(d) By the condensation of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of pyrimidines92.
(e) By the condensation of thiourea and substituted ß-ketoester in presence
of sodium ethoxid e led to formation of 2-mercaptopyrimidines93.
(f) By the condensation of chalcones with dicyandiamide in presence of
piperidine led to formation of pyrimidines94.
(g) By thermal or microwave irridiation of thiourea and substituted ß-ketoester
in presence of dimethylformamide led to formation of substituted tetrahy-
dropyrimidines95.
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(h) One pot synthesis of substituted dihydropyrimidin-2-ones catalysed
by CuCl2
96.
(i) Synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones under micro
wave irradiation97.
(j) One pot efficient and novel synthesis of dihydropyrimidin-2-(1H)-ones
catalysed by Tin (II) chloride (SnCl2)
98.
(k) By microwave induced eco-friendly solvent free Biginelli reaction catalysed
by calcium chloride99.
Pyrimidines have found their applications as herbicidal100 and pesti-
cidal101-102  agents. Yoshida et.al.,103  have synthesized 4-amino-5-formyl-2-
mercaptopyrimidines  as agrochemical intermediates.  C. Srivastava  et. al.,104
have synthesized new substituted pyrimidines (19) as  potential insecticides.
N. Yasushi et al.,105  synthesized 6-(1-fluoroethyl)-5-iodo-4-alkylamino pyrim-
idines (20) as pesticides for agriculture and horticulture. Besides such a great
biological importance of pyrimidines , they also contribute to an important class
of dye viz. trichloro pyrimidine106  dye which is a reactive dye. Pyrimidines
also have applications in liquid crystal composition.107  Many synthetic members of















PHARMACOLOGICAL IMPORTANCE OF PYRIMIDINES
Numerous pyrimidines are well known drugs for variety of diseases. They
may be placed in four categories viz. barbiturates, sulfonamides, antimicrobi-
als and antitumor agents. Uracil, thymine, alloxan, vicine and divicine,
cytosine, chroticacid , willardiline , tetradotoxine, becimethrian (21),
blasticidine (22) , cougerotin , amicetin , bamicetin and plicacetin ,
phleomicine , blemycin and related families (23).
(19)
R = Alkyl/Aryl (20)






















Pyrimidine derivatives have wide varieties of usages. Pyrimidine ring sys-
tem is also present in Vitamin B 2 and folic acid . Pyrimidine ring system having
a mercapto group occupy a unique position in medicinal chemistry. 109 These types
of derivatives play a vital role in biological processes110-112 as well as synthetic
drugs.113
Some of the the rapeutic activities of pyrimidine derivatives can be sum-
marized as follows .
(a) Antithyroid 114,115 (b)      Antitumor116-118
(c)      Antihypertensive119-121         (d)      Antiinflammatory122-124
(e)      Diuretic125 (f)       Antimalarial126-128
(g)      Antispasmodic 129 (h)      Anticonvulsant130
(i)       Antineoplastic 131,132 (j)       Anthelmintic133
(k)      Antimicrobial134-159 (l)       Cardiovascular160-162
(m)     Antiviral163-166 (n)      Platelet aggregation inhibitor167,168
(o)      Antihistamine169,170 (p)      Anti-HIV171,172
(q) Antitubercular173
The basis of any rational drug discovery programme is fundamently, the
Medicinal Chemistry. Although the synthesis of modified nucleic acids has been a
subject of interest for some time, the intense focus on the medicinal chemistry of
oligonucleotides dates perhaps to not more than five years. As a result of this,
the scope of medicinal chemistry has recently been expanded enormously, but the
biological data of supporting the conclusions about synthetic strategies have just
begun to emerge.
Modifications in the base, sugar and phosphate moeities of oligonucleotides
and oligonucleotide conjugates have been reported. The subjects of medicinal
chemical programmes include approaches to create enhanced affinity and more
(21) (23)(22)
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selective  affinity for RNA or duplex structures, the ability to cleave nucleic acid
targets, enhanced nuclease stability, cellularuptake and distribution, in vivo  tis-
sue distribution, metabolism and clearance. Although substantial progress in the
medicinal chemistry of oligonucleotides has been made in the past three years, it
is not yet possible to reach the conclusion about the therapeutic ability of the novel
modifications. Preliminary data on effects on nuclease stability and hybridization
properties for a few modifications and activity in vitro suggest that the next
generation of oligonucleotides may display substantially improved potencies and
selectivity.
PYRIMIDINE MODIFICATIONS (Nucleotide)
A relatively large number of modified pyrimidines have been synthesized
and now incorporated into oligonucleotides and evaluated. The principle sites
of modification are C-2, C-4, C-5 and C-6 (24). These and other nucleoside













In as much as the C2 position is involved in Watson-Crick hybridization,
oligonucleotides containing C2 alkyl modified  pyrimidines have shown unattrac-
tive hybridization characters. However, an oligonucleotide containing 2-thioth-
ymidine (25) was found to hybridize well to DNA and, in fact even better to RNA
with a thermal melting temperature (DTm) value of 1.5 °C/modification. In a differ-
ent study, oligoribonucleotides  with 2’-o-methyl-2-thiouridine (26) exhibited a
thermal melting temperature (DTm) value of +5.5°C/modification when hybridized
against RNA resulting from a highlly preoganized RNA-like C3’-endo conforma-
tion (attributed to the combination of 2-thio modification and 2’-o-Mesubstituent) .
Oligonucleotides with this modification also exhibit better hybridization discrimi-
nation for the wobble uracil-guanosine (U-G) base pair formation compared to the
(24)
Sites of pyrimidine Modification
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normal uracil-adenine (U-A) base pair. This selectivity is a result of weaker

















In contrast, the pyrimidine modifications in 4-position with interesting prop-
erties have been reported. 4-Thiopyrimidines (27,28) have been incorporated into
oligonucleotides with no significant negative effect on hybridization.However,
recent studies have shown destabilization in the normal uracil-adenine  (U-A) base
pair formation and stabilization of the wobble uracil-guanosine (U-G) base pair
for 4-thiouridine . A bicyclic and an 4-methoxy analog of cytosine were shown to
hybridize with both purine bases in DNA with thermal melting temperature (Tm)
values approximately equal to that of natural base pairs.  Additionally, a fluores-
cent base has been incorporated into oligonucleotides and shown to enhance
DNA-DNA duplex stability. 176















The pyrimidine modification at C 5 position including halogenated nucleo-
sides have been reported. Although the stability of duplexes may be enhanced by
incorporation 5-halogenated uracil containing nucleosides, the occasional
mispairing with guanidine and the potential that the oligonucleotide might
degrade and release toxic nucleosides analogs cause concern. Oligonucleotides
(25) (26)
(27) (28)
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containing 5-propynylpyrimidine (30,31)  modification have been shown to en-
hance the duplex stability thermal melting temperature (DTm = 1.6°C/modification ),
and support RNase H activity. The 5-heteroaryl-pyrimidines  were also shown to
increase the stability of duplexes. A more dramatic influence was reported for the
tricyclic 2’-deoxycytidine  analoges, termed phenoxazine, exhibiting an enhance-

























As expected, modifications in the C6 position of pyrimidines are highly
dupled destabilizing. Oligonucleotides containing 6-azapyrimidines (32)  have
been shown not only to reduce the  thermal melting temperature (Tm) value by 1-
2°C per modification, but also to enhance the nuclease stability of oligonucleotides














The increasing interest in the early 1970s in properties and use of interferon
(IFN) together with the difficulty in producing useful amounts of interferon (IFN) led
to the search for agents that would induce IFN in the host. Precedenced at that
time for interferon (IFN) inducers included viruses and bacterial wall constituents and
(29) (30) (31)
(32)
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entities of large molecular weight such as the polynucleotides. There were also
several examples of low molecular weight substances such as certain antibiotics
and the antiviral agent, tilorone.179,180 In 1976 it was reported that 6-methyl
pyrimidinone(2-amino-5-bromo-6-methyl-4-(3H)pyrimidinone, ABMP) induced
circulating levels of interferon (IFN) in several animal specis upon oral or intraperitoneal
administration.181  Subsequent structure-activity studies yielded a more potent and
less toxic 6-phenyl ananlog called ABPP or bropirimine (2-amino-5-bromo-6-phenyl-4-
(3H)pyrimidinone) (figure 1 and Table 1).182 ,183  Bropirimine  and related 6-aryl
analogs  were examined extensively for efficacy in virus and tumor models, along
with their immunomodulatory properties and overall pharmacological effects.184

















 Figure 1 :  Preliminary SAR of antiviral activity  of pyrimidinones
                                     (underlined substituents were active)
Table - I
Antiviral Activity
monosubstituted Disubstituted       Heterocyclic
Active         2-F,OMe, Me 3,5-OMe 1-Naphthyl






















                                         2-Quinoline
As with the polynucleotides, the pyrimidinones exhibited significant activ-
ity against interferon (IFN) sensitive viruses such as Semliki Forest virus in vivo. How-
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ever, in addition, they exhibited prophylactic and therapeutic activity upon    either
local or systemic administration to rodents infected with a variety of DNA viruses ,
such as the herpes viruses (HSV-1, HSV-2 , CMV  and pseudorabies), and when
administered intranasally for upper respiratory infections, such as infectious
bovine rhinortacheites, inf luenza A and  para-influenza-3. Particularly
interestion activity was noted  with bropirimine on intravaginal administration in
protection against  HSV-2  intravaginal infection in guinea pigs, an important model
for genital herpes  in humans.185  Bropirimine  also exhibited activity when given
either intraperitoneally or orally to mice infected with Listera monocytogenes .
The efficacy in this model  was not abrogated by the addition of anti-interferon
(IFN)  antibody.186
Pyrimidines as Antifolates
        During a preliminary clinical trial designed to establish safety and suitability
for use in the treatment of cancer, Farber found the folic acid  derivatives
pteroyldiglutamic acid (33)  and pteroyltriglutamic acid (34)  were accelerat-
ing the growth of malignant cells in the bone marrow of patients with acute leu-
kaemia. He obtained the newly synthesized antifolate pteroylaspartic acid  from
Subba Row,  from which encouraging results were obtained in children with acute
leukaemia. Better responses were observed with the aminopterin (35) and meth-
otrexate  (36). Injections of methotrexate induced temporary remissions in 30%
of children, but Farber and his colleagues later combined it with drugs such as
cortisone  and mercaptopurine  to achieve results which paved the way towards
the currentposition where most children can be cured of the disease if given the
appropriate treatment. The precise model of action of the antifolates became
apparent in 1952. This was the inhibition of dihydrofolate reductase, the enzymes
that catalysed the transformation of folic acid so that it could be utilized for the
synthesis of thymine for incorporation into DNA. Surprisingly, no other antifolate




















COOH (34)   n =2,  R = OH











Of the various halogenated pyrimidines which have been prepared, only
the fluorinated pyrimidines and nucleosides have useful antitumour activity, and
of these the most significant are 5-fluorouracil (FU) and it’s 2’-deoxyribo-
nucleside (FUdR; Floxuridine) . Both of these drugs have found wide uses in
patients suffering from metastatic cancer, and have been administered both
singly and in combination therapy.
The presence of flourine, which cannot be abstracted by base, halts the
process. In contrast, the 5’-monophosphate  of 5- chloro-, 5- bromo- and 5-iodo-
2’-deoxyuridine , in which the halogen atom is bulkier and less electronegative,
have little or no useful inhibitory activity for the enzyme. The drugs of fluorouracil (FU)
showing good antitumour activity includes it’s 1-t-butylcarbamoyl187 ,1-hexy-
lcarbamoyl188 and 1-methoxycarbonylmethylcarbamoyl189 derivatives, 5’-
deoxy-5-fluorouridine190 and methyl-1-(5-fluoro-1-H-2-oxopyrimidin -4-yl)-B-
D-glucopyranuronate  (37).191 All of these contain in essence the  fluorouracil
(FU) moiety, ready via oxidative or hydrolytic means. 5-Fluoropyrimidin-4(1H)-one,
with activity against tumours in experimental animals, is a different type of prod-
rug,being oxidized to 5-fluorouracil (FU) by xanthine oxidase.192
A number of prodrugs of FUdR have also been prepared a notably potent
member being 5-bromo-6-methoxydihydro-5-fluro-2’-deoxyuridine  (38).193
finally, a different species of fluoro-pyrimidine  derivative, which as its 5’-mono-
phosphate inhibits thymixylate  synthetase is 5-trifluoromethyl-2’-deoxyuridine
( Trifluridine ; 39)  it possesses a higher therapeutic index against adenocarci-

























    (19)    R = H                   (20)  R = Me
 (37)                          (38)                                       (39)
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As part of a continuing effort of develop novel classical antifolates as
dihydrofolates (DHFR) inhibitors and as antitumor agents, A. Gangjee et. al.,195
have reported the 5-substitutedfuro[2,3-d]pyrimidins (40) for enzyme inhibi-






PYRIMIDINES AS ANTITUMOUR AGENTS
A number of other pyrimidine antagonists displaying antitumour activity,
in which the base is conjugated to a modified suger ring have been reported. Al-
though D-Arabinofuranosyl uridine (ara-uridine) shows no useful acitivity,  and
5-bromo- and 5-iodo-D-arabinofuranosyl uridine inhibit the growth of  sarcoma
180 and L1210 cells in culture.196 Other thymidine analogues with similar activity
include 5-azidomethyl-,5-aminomethyl and 5-hydroxymethyl-2’-deoxyu-
ridine197. 3’-Amino-3’-deoxy thymidine198  and 3’-amino-2’,3’-dideoxycy-
tidine199  also posses strong activity against L1210 leukaemia 2’-Deoxy-2’-
fluoro-5-methyl-1-B-D-arabinofuranosyluracil (FMAU; 41) is highly active
against arabinofuranosyl cytidine (ara-C) resistant L1210 and P815 cell lines both
in vitro and in vivo.200 2-B-D-Ribofuranosylthiazole-4-carboxamide
(Tiazofurin; 42) has aroused much interest recently for its activity against solid
tumour such as lung carcinoma . It is metabolized to an analogue of NAD in which
the thiazole-4-carboxamide  moiety replaces the nicotinamide ring. However, it
also depresses the synthesis of DNA and RNA, and thus merits inclusion as an















* * Antagonist  : A chemical substance that interferes with the physiological action of another, especially
by combining with and blocking its nerve receptor.
(41)       (42)
(40) n = 4
Studies on pyrimidines... 108
Targets for Antiviral Chemotherapy
Viral chemotherapy presents a quite different problem from tumor
chemotherapy. A virus202 consists of a core of nuclear material, DNA or RNA,
containing specific viral genes, which may be associated with ‘core proteins’, and
which is surrounded by a protective proteincoat. The coat may have functional pro-
tein appendages, and there may be present an ‘envelope’, rich in lipoprotein and
glycoprotein. The virus possesses no energy-producing or protein-synthesizing
machinery of its own. In order to reproduce, it must therefore become adsorbed to
a host cell, be transported across the cell membrane, and uncoat in order that its
viral genes may be expressed. The genome may require to be transported to the
cytoplasm or the nucleus. The nuclear material must then be replicated, and the
viral genes also transcribed into RNA (assuming that we are dealing with a DNA
virus) and  translated into virally specified protein. In addition to the coat protein,
viral enzymes will be produced in this process, and these are vital for suborning
the host cell’s internal biochemistry to serve the requirements of the virus. Before
the viral proteins can be made, a process of maturation of the viral mRNA mol-
ecules, involving guanylylation and methylation to produce a ‘cap’ structure con-
taining 7-methylguanosine 5’-phosphate  in a 5’- 5’-pyrophosphate  structure
at the 5’- end of the mRNA, must occur. Once the synthesis of the components
needed to make fresh viral particles has been completed, maturatian occurs, in
which the nucleic acid and protein components are assmbled to from the com-
plete viral   particle or virion, and finally this is released from the cell as a new ,
infective virus. RNA viruses require that their nucleic acid be replicated also, in
order that new viral particles can form. Some RNA viruses code for an enzyme
‘transcriptase’ or ‘replicase’ (RNA-directed RNA polymerase), which  replicates
RNA strands directly without involving DNA203 while others encode an enzyme
‘reverse transcriptase’ (RNA-directed DNA polymerase), which transcribes the
RNA sequence into DNA-the reverse of the usual sequence which can subsequently
become integrated into the host cell chromosome and is transcribed to from cop-
ies of the viral RNA.204  Purine and pyrimidine antimetabolites which are active
against viruses are thus most likely to be effective by inhibiting specifically the
viral enzymes which are required to replicate the viral nucleic  acids, or inhibiting
the viral enzymes responsible for transcription and capping of mRNA, without  in-
* * Agonist : A drug which binds to a receptor and activates it, producing a pharmacological response.
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hibiting the corresponding enzymes of the host cell.
Alternatively, incorporation of an antimetabolite into a viral nucleic acid
causing the cessation of strand synthesis, or otherwise disturbing the normal function
of the nucleic acid in replication or in directing protein synthesis, offers another
way of preventing the replication of functional virus.205  Again, it is important that
the   integrity of the nuclear material of the host cell should not be compromised.
One therefore seeks to exploit the differences between the viral enzymes to the
discomfiture of the virus.
5’-Amino-5-iodo-2’,5’-dideoxyuridine(Aminoidoxuridine; 44) displays good
antiherpes  activity and is less cytotoxic than (43).206,207  The phosphorylation
of Aminoidoxuridine (44) is catalyzed specifically by virus-induced thymidine kinase,
and thus Aminoidoxuridine(44)  is only potentiated in virus-infected cells. It inhib-
its the synthesis of DNA in infected cells. The 5-bromo-, 5-chloro- and 5-trifluoro-
methyl derivatives of 5’-amino-2’,5’-dideoxyuridine  also exhibit antiviral activ-
ity208 . 5-Iodo-2’-deoxcytidine (45) and 5-bromo-2’-deoxycytidine (46) also
show useful activity against herpes viruses and vaccinia with less cytotoxicity than
the uridine compounds and more selective inhibition of virus replication. C. K.
Chu209  et. al., have prepared pyrimidine nucleosides  (47) and reported in vitro
antiviral activity against varicella zoster virus (VZV).



























(43, 44) R = OH, NH2 (45,46) X = I, Br (47) X = Cl, Br, I
PYRIMIDINES AS ANTI-HIV AGENTS
The strategy of designing nucleoside analogs that are selective for viral
DNA polymerases is the most well-studied and successful approch to viral che-
motherapy, and has led to the discovery of several clinically useful antiviral drugs.
This strategy, however, has inherent limitations. Human DNA polymerases also
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required dNTP’s and the chemical mechanisms of polymerization by the viral and
human enzymes are similar. Nucleoside analogs often have significant host toxicity
that is probably related to inhibition of host cell DNA synthesis. Nevertheless, these
compounds constitute the major class of antiviral drugs, and this approach is
likely to yield additional active compounds in the near future. For the long term,
however, other strategies may ultimately lead tonmmore selective agent withn lower
toxicity.
Obviously, the key to design analogue with a lower affinity for the host enzyme
than the viral enzyme, which requires that there be structural differences between
the enzyme active sites. For reverse transcriptase, the most well studied inhibitor










3’-azido-3’-deoxythymidine (AZT) inhibits HIV reverse transcriptase with an
IC50 of 40nM212 , but is 100-300 times less active against mammalian DNA poly-
m erase a  and DNA polymerase g . The reason for this selectivity is not clear since
3’-azido-3’-deoxythymidine (AZT) is a chain terminator for mammalian DNA poly-
merases and inhibits normal cel lular DNA synthesis.213  Several other
dideoxynucleoside analogs have been shown to be potent inhibitors of HIV
replication in vitro.214,215  In general, these compounds have the same mechanism
of action as 3’-azido-3’-deoxythymidine (AZT), that is, intracellular conversion
to the triposphate derivative and subsquent inhibition of HIV reverse tran-
scriptase .
Some of these compounds are simply analogs of the nautral 2’-deoxy-
nucleoside  in which the 3’-OH group has been replaced with a hydrogen, such as
2’,3’-dideoxycytidine(49), 2’,3’-dideoxyadenosine(50 ) and 2’,3’-dideo-
xythymidine (51). Other analogs contain a 2’-3’ double bond, such as 2’3’-
didehydro-2’,3’-dideoxythymidine (52).  Several related analogs with other modi-
fications to the ribose ring or the heterocyclic base moiety have also been re-
(48)
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Recently, P. Khalili et. al.,218  have carried out biochemical and pharmaco-
kinetic evaluation of a novel nitric oxide donor pyrimidine nucleoside hybrid drug
as a potential anticancer / antiviral agent. Rostom et al.219  have synthesized and
screened certain 2-(benzoxazol-2-yl-amino)-3H-4-oxopyrimidines  for in vitro
anti-HIV  activity.
R. A. Nugent et. al.,220  have synthesized pyrimidine thioethers (53) and
evaluated for inhibitory properties against wild-type HIV-1 reverse transcriptase.
F. Manetti et. al.,221  have synthesized novel pyrimidines (54) with nanomolar






















R = Ph, Me, CO2Me,     




A family of trisubstituted pyrimidines has been described as selective  COX-
2 inhibitors. To explore the usefulness of pyrimidine derivatives as potential
NSAIDs . Aurelio Orjales et. al.,222  have synthesized novel pyrimidine deriva-
tives (55) and (56).
             (49)              (50)                (51)             (52)
(53)                (54)
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In vitro biological evaluation of these compounds has provided information












(55) Y = CH; X, Z = N      (56)  Y, Z = N; X = CH
In view of procuring highly potent biodynamic agents and after reviewing
recent literature survey on 2-hydroxy / mercapto / aminopyrimidines  for their
various methods of synthesis and different pharmacological activities, synthesis
of pyrimidines have been undertaken which can be summarized in the following
sections as  follows:
SECTION  - I : PREPARATION AND BIOLOGICAL SCREENING OF 1-ARYL- 3-
(3’ -PHENOXYPHENYL)-2-PROPEN-1-ONES .
SECTION  - II : PREPARATION AND BIOLOGICAL SCREENING OF 2-AMINO-
6-(3’-PHENOXYPHENYL)-4-ARYL-1,6-DIHYDROPYRIMIDINES .
SECTION  - III : PREPARATION AND BIOLOGICAL SCREENING OF 2-MERCA-
PTO-6-(3’-PHENOXYPHENYL)-4-ARYL-1,6-DIHYDROPYRIM-
IDINES .
SECTION  - IV : PREPARATION AND BIOLOGICAL SCREENING OF 2-HYDRO-
XY-6-(3’-PHENOXYPHENYL)-4-ARYL-1,6-DIHYDROPYRIMI-
DINES.
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SECTION - I
PREPARATION AND BIOLOGICAL SCREENING OF 1-ARYL-3-(3’-
PHENOXYPHENYL)-2-PROPEN-1-ONES .
Due to various biodynamic activities114-173of pyrimidines and with a
view to have potent therapeutic agents, the synthesis of 1-aryl-3-(3’-phenoxy-
phenyl)-2-propen-1-ones  (g1-8) have been undertaken by the condensation of




The constitution of the products (g1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (g1-8) were assayed for their in vitro biological assay like
antibacterial activity  towards S. pyogens MTCC-442, S. aureus MTCC-96  and
B. subtil l is MTCC-441  (Gram posit ive) and E. coli  MTCC-443  (Gram
negative) bacterial strain and antifungal activity  towards A. niger  MTCC-282
and C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (con-
trol), 5, 10, 25, 50, 100, 200, 500. The biological activities  of the synthesized
compounds were compared with standard drugs  viz. Ampicillin , Chloram-
phenicol, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifun-
gal).
(g1-8)              R=Aryl


































































































Studies on pyrimidines... 115
























Internal Standard : TMS ; Solvent : CDCl3, DMSO; Instrument : BRUKER Spectrometer
(300 MHz)































































































































m/z = 300 (M -1)
m/z = 222 (M-1)
m/z = 166 (M-1)
m/z = 152
m/z = 238 (M -1)
m/z = 92 (M-1)
m/z = 314 (M+2) (BP)
m/z = 77
m/z = 120 (M -1)
m/z = 140 (M-1)
m/z = 102
m/z = 204 (M+1)
m/z = 192
m/z = 286 
m/z = 178
m/z = 270 (M+1)
+
(g6)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 1-ARYL-3-( 3’-
PHENOXYPHENYL)-2-PROPEN-1-ONES .
(A) Preparation of 1-(4’’-methylphenyl ) -3-(3’-phenoxyphenyl)-2-propen-
1-one (g6).
A mixture of p-methylacetophenone (1.34 ml, 0.01 M) in methanol (20ml),
m-phenoxybenzaldehyde  (1.98 ml, 0.01 M) in methanol (20ml) and aqueous
KOH (40%, 2ml) were stirred for 24 hrs. at  room temprature. The content was
poured on crushed ice and neutralized with HCl. The  product   was isolated and





 : 0.50 (Required :  C: 84.08%; H: 5.73%  for C22H18O2, Found : C: 84.04%; H:
5.68% ).
Similarly, other compounds  (g1-8) were synthesized. The physical data
are recorded in Table No. 7.
(B) Antimicrobial activity of 1-aryl-3-(3’-phenoxyphenyl)-2-propen-1-
ones (g1-8).
Antimicrobial activity testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zones of inhibition of test solution are recorded in Table
No. 7a, 7b & 7c.
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SECTION - II
PREPARATION AND BIOLOGICAL SCREENING OF 2-AMINO-6-(3’-
PHENOXYPHENYL)-4-ARYL-1,6-DIHYDROPYRIMIDINES .
Due to various biodynamic activities114-173  of pyrimidines and with a
view to have potent therapeutic agents, the synthesis of 2-amino-6-(3’-phenoxy-
phenyl)-4-aryl-1,6-dihydropyrimidines (h1-8) have been undertaken by the
condensation of different 1-aryl-3-(3’-phenoxyphenyl)-2-propen-1-ones  with







The constitution of the products (h1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (h1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram negative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500. The biological activities  of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(h1-8)     R=Aryl
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Internal Standard : TMS ; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer    (300
MHz)


























































































































m/z = 299 (M-2)
m/z = 198
m/z = 314 (M+1)
m/z = 222 (M-1)
m/z = 187
m/z = 355 (M+2) (BP)
m/z = 119
m/z = 92(M-1)  
m/z = 77
m/z = 265








m/z = 163 (M+2)
(h6)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-AMINO-6-(3’-
PHENOXYPHENYL)-4-ARYL-1,6-DIHYDROPYRIMIDINES .
(A) Preparation of 1-(4’’-methylphenyl)-3-(3’-Phenoxyphenyl)-2-propen-1-
one (g6).
For preparation refer Part - IIA, Section - I, Page No.119.
(B) Preparation of 2-amino-6-(3’-phenoxyphenyl)-4-(4’’-methylphenyl)-1,
6-dihydropyrimidine (h6).
A mixture of 1-(4’’-methylphenyl)-3-(3’-phenoxyphenyl)-2-propen-1-
one  (3.14 gm, 0.01 M) and guanidine hydrochloride  (0.96 gm, 0.01 M) in alco-
holic KOH was refluxed for 8 hrs. in waterbath. The content was allowed to cool
overnight.The solid seperated was filtered and recrystallized in DMF . Yield :76%,
M.P. :158°C, Rf
1
 : 0.56, Rf
2
 : 0.52   (Required :  C: 77.75%; H: 5.91%; N: 11.83%
for C23H21N3O, Found : C: 77.71%; H: 5.88%; N: 11.78% ).
Similarly, other compounds  (h1-8) were synthesized. The physical data
are recorded in Table No. 8.
(C) Antimicrobial activity of 2-amino-6-(3’-phenoxyphenyl)-4-aryl-1,6-
dihydropyrimidines (h1-8).
Antimicrobial activity testing was carried out as described in part-I, sec-
tion-I, page No. 33. The zone of inhibition of test solution are recorded in Table
No.8a,8b & 8c.
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SECTION - III
PREPARATION AND BIOLOGICAL SCREENING OF 2-MERCAPTO-6-
(3’-PHENOXYPHENYL)-4-ARYL-1,6-DIHYDROPYRIMIDINES .
Due to various biodynamic activities114-173  of pyrimidines and with a
view to have potent therapeutic agents, the synthesis of 2-mercapto -6-(3’-pheno-
xyphenyl)-4-aryl-1,6-dihydropyrimidines  (i1-8) have been undertaken by the
condensation of different 1-aryl-3-(3’-phenoxyphenyl)-2-propen-1-ones  with







The constitution of the products (i1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (i1-8) were assayed for their in vitro biological assay like
antibacterial activity  towards S. pyogens MTCC-442, S. aureus MTCC-96  and
B. subtil l is MTCC-441  (Gram posit ive) and E. col i  MTCC-443  (Gram
negative) bacterial strain and antifungal activity  towards A. niger  MTCC-282
and C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (con-
trol), 5, 10, 25, 50, 100, 200, 500. The biological activities  of the synthesized
compounds were compared with standard drugs  viz. Ampicillin , Chloram-
phenicol, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifun-
gal).
(i1-8)           R=Aryl
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Frequency in cm-1
Observed Reported
ReferenceType  Vibration  mode
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Internal Standard : TMS ; Solvent : CDCl3, CHCl3; Instrument : BRUKER Spectrometer
(300 MHz)
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m/z = 188 (M-2)
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m/z = 170 (M-1)
NH2
NH


















Studies on pyrimidines... 140
REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-MERCAPTO-
6-(3’- PHENOXYPHENYL)-4-ARYL-1,6-DIHYDROPYRIMIDINES .
(A) Preparation of 1-(4’’-methylphenyl)-3-(3’-Phenoxyphenyl)-2-propen-
1-one (g6).
For preparation refer Part - IIA, Section - I, Page No. 119.
(B) Preparation of 2-mercapto-6-(3’-phenoxyphenyl)-4-aryl-1,6-dihydro-
pyrimidine (i6).
A mixture of 1-(4’’-methylphenyl )-3-(3’-phenoxyphenyl)-2-propen-1-
one  (3.14 gm, 0.01 M) and thiourea (0.76 gm, 0.01 M) in alcoholic KOH was
refluxed for 8 hrs. in waterbath. The content was allowed to cool overnight. The
solid seperated was filtered and recrystallized in DMF:methanol (1:2) . Yield :
64%, M.P. : 206°C, Rf
1
 : 0.59, Rf
2
 : 0.62    (Required :  C: 74.19%; H: 5.38%; N:
7.53% for C23H20N2OS, Found : C: 74.15%; H: 5.34%; N: 7.49% ).
Similarly, other compounds  (i1-8) were synthesized. The physical data
are recorded in Table No. 9.
(C) Antimicrobial activity of 2-thio-6-(3’-phenoxyphenyl)-4-aryl-1,6-dihy-
dropyrimidines (i1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table
No. 9a, 9b & 9c.
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SECTION - IV
PREPARATION AND BIOLOGICAL SCREENING OF 2-HYDROXYO-6-
(3’-PHENOXYPHENYL)-4-ARYL-1,6-DIHYDROPYRIMIDINES .
Due to various biodynamic activities114-173  of pyrimidines and with a
view to have potent therapeutic agents, the synthesis of 2-hydroxy-6-(3’-pheno-
xyphenyl)-4-aryl-1,6-dihydropyrimidines  (j1-8) have been undertaken by the
condensation of different 1-aryl-3-(3’-phenoxyphenyl)-2-propen-1-ones  with







The constitution of the products (j1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (j1-8) were assayed for their in vitro biological assay like
antibacterial activity  towards S. pyogens MTCC-442, S. aureus MTCC-96  and
B. subtil l is MTCC-441  (Gram posit ive) and E. col i  MTCC-443  (Gram
negative) bacterial strain and antifungal activity  towards A. niger  MTCC-282
and C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (con-
trol), 5, 10, 25, 50, 100, 200, 500. The biological activities  of the synthesized
compounds were compared with standard drugs  viz. Ampicillin , Chloram-
phenicol, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifun-
gal).
(j1-8)         R=Aryl
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   Internal Standard : TMS ; Solvent : CDCl3, DMSO; Instrument : BRUKER Spectrom
   eter  (300 MHz)


















































































































m/z = 356 
m/z = 207 (M-2)
m/z = 340 (M-2) m/z = 313 (M-1)
m/z = 299 (M-2) (BP)
m/z = 223 (M-2)
CH3
m/z = 171 (M-2)m/z = 131 (M-2)
m/z = 114 (M+1)
m/z = 92 (M-1)
m/z = 77 
+
(j6)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-HYDROXY-6-(3’-
PHENOXYPHENYL)-4-ARYL-1,6-DIHYDROPYRIMIDINES .
(A) Preparation of 1-(4’’-methylphenyl ) -3-(3’-phenoxyphenyl)-2-propen-
1-one (g6).
For preparation refer Part - IIA, Section - I, Page No.119.
(B) Preparation of 2-hydroxy-6-(3’-phenoxyphenyl)-4-(4’’-methylphe-
nyl)-1,6-dihydropyrimidine (j6).
A mixture of 1-(4’’-methylphenyl )-3-(3’-phenoxyphenyl)-2-propen-1-
one  (3.14 gm, 0.01 M) and urea (0.60 gm, 0.01 M) in alcoholic KOH was refluxed
for 8 hrs. in waterbath. The content was allowed to cool overnight.The solid
seperated was filtered and recrystallized in dioxane:methanol (1:2). Yield : 58%,
M.P. : 83°C, Rf
1
 : 0.41, Rf
2
 : 0.62 (Required :  C: 77.53%; H: 5.62%; N: 7.86% for
C23H20N2O2, Found : C: 77.49%; H: 5.58%; N: 7.82% ).
Similarly, other compounds  (j1-8) were synthesized. The physical data
are recorded in Table No. 10.
(C) Antimicrobial activity of 2-hydroxy-6-(3’-phenoxyphenyl)-4-aryl-1,6-
dihydropyrimidines (j1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table
No. 10a, 10b & 10c.
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PART - II-B
STUDIES ON 4-PYRIMIDINYL SULPHONAMIDES
INTRODUCTION
General formula of sulphonamides is -R-SO2-N-R’-R”. In sulphonamide groups
R,R’,R”  can be hydrogen / alkyl / aryl / heterocyclic  moiety. The initial discov-
ery of  the sulphonamides was largely the result of serendipity. At the turn of the
century a wide variety  of azo dyes were in use and continuous efforts were beiging
made to improve the properties of these very useful compounds. It became popu-
lar to introduce the sulphonamide group (57), which often gave the dyes extra
light stability, greater water solubility during application and a greater fixation to
certain fibres, particularly proteins such as wool. Of note were observations  such
as that made in 1932 that  the dye prontosil (58)  possessed effective bacteri-
cidal properties in vivo  in small animals, for example the protection of mice
against streptococcal infection223 . This observation stimulated further studies
and shortly afterwards, in 1933, prontosil was used clinically in case of
staphylococcalse pticaemia 224 .
    R1 = Aryl or Heteroaryl group
    R2 = H, Alkyl, Aryl or Acyl group
During clinical studies it was confirmed that, where as prontocil was active
in vivo  assays proved ineffective. Attempts to modify the molecule showed  that
variations in the nonsulphonamide contaning portion of the azo dye had little
effect on in vivo  potency, only varying  degrees of consequence,different  poten-
cies and ranges of activity beging observed.225 The subsequent finding that
prontosil was metabolized in vivo  to give sulfanilamide (59) . Rapid progress
in the clinical use of the latter and a range of related compounds became pos-
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facture and that since it was a well-known compounds, first prepared in 1909226










The sulphonamides , predating the penicillins , were thus the first group
of chemical compounds to be widely used as specific antibacterial agents. The
aliphatic sulphonamides have not yet become important. Development of the
sulphonamide led for the first time to the design evaluated clinical trials and these
in turn, resulted in important obversations on their side effects. Some of these
proved to give unexpected benefits eventually harnessed as new drug leads and
the application of various sulphonamides derivatives in other important chemo-
therapeutic areas, such as their use as diuretics227, as orally active antidi-
abetics228 . Alongside the clinical studies, fundamental work on the mode of
action of the sulphonamides commenced. The first clue on this was the observa-
tion by woods229  that the in vitro antibacterial action of the sulphonamides
could be reversed by addition od p-aminobenzoic acid  (61). This observation
suggested that the sulphonamides acted as a competitive antagonist to the natu-
rally occurring PABA, known to be an essential growth factor for some microor-
ganisms, i.e that they are acting as antimetabolites . The concept of antimetabo-
lites developed by Fildes230  and has subsequently been applied to several other
areas of chemotherapy, notably in the nucleotide area. The early interest in the
sulphonamides has been maintained to the present and the studies on seperating
out the beneficial side effects from the antibacterial properties have helped to
established methods for developing new leads from drugs as well as protocols for
toxicological studies. Finally, because of their relatively simple structure many
variations and analogues have been synthesized and these in turn have helped to
established the principles for optimizing drug design. Aromatic and heterocyclic
sulphonamides have achieved great commercial significance as their applica-
tion shown in the chemistry of sulphonamides due to their use as antibacterial,
anticancer , antimalarial, antifungal,  antiplasmodic , anticonvulsant, herbi-
cidal, pesticidal, antiinflammatory and analytical preparation.
(59)                                                        (60)




CHEMICAL STRUCTURE OF THE SULPHONAMIDE GROUP
The availability of many crystalline derivatives of sulphonamides drugs
has given scope for several structural studies. The sulphonamide group is strongly
electron attracting, leading to a high electron density on the sulfone oxygen atoms
and enhanching the acidity of the proton attached to nitrogen; N-unsubstituted or
mono substituted sulphonamides behave as acids and readily forms salts. Struc-
turally the atoms linked to the central hexavalent sulfur atoms are arranged tetra-
hedrally, as exemplified by the structures of the drugs hydrochlorothiazide (62)231
and torasemide (63)232  which behave as diuretics ,233  and sulthiame (64)234.
The pK
a
 values of sulphonamides bearing a N-H bond are generally in the range
4-9. Because of this the simple N-unsubstituted group has often been compared
to a carbonyl group, i.e. a carbonyl isostere; the structure of sulphonamide (59)
and (61) are very similar. Thus in the mejority of biological situations the sulphon-
amides are likely to be present as salts, although for transport through membranes
etc., the unionized form is likely to be more easily transported, hence the pK
a
 value





























In sulphonamide in which the nitrogen is further conjugated, such as
sulphaguanidine (65)235  and  sulfapyridine236 the doubly bonded nitrogen is
the prefered tautomer. 237  Finally, in any intermolecular interactions account must
be given of the large dipole moment associated with sulphonamide group and
(61)
(62)                                          (63)                                       (64)
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surface charges, particularly those placed on the oxygen atoms. During attempts
to find active variations in the sulphonamide structure it was found that some
diarylsulfones also acted as antagonists of PABA, for example the agent
dapson (66) ,238 which is still particularly useful in mycobacterial infections such
as leprosy .239 The structure-activity studies have demonstrated that these bind
in a similar manner to sulphonamides , substituents reinforcing negative charge













(65)       (66)
SYNTHETIC METHODS OF SULPHONAMIDES
The synthesis of sulphonamides have been reported in the literature.240-241
THERAPEUTIC IMPORTANCE OF  SULPHONAMIDES DERIVATIVES
The sulphonamides inhabit growing bacterial organisms . Considerable
research has been undertaken to extend the activity and reduce toxicity of sulpha
drugs. Monogram and review242,243  surveying  various aspects of sulpha drugs
have been published. The sulphonamides have been found to possess following
types of activity.
(a) Antihypertensive244 (b) Diuretic245-247
(c) Anticonvulsant248 (d) Antitumor249,250
(e) Herbicidal251,252 (f) Antiviral253
(g) Antimalarial254 (h) Antimicrobial255-261
(i) Hypoglycemic262,263 (j) Cardiovascular264
(k) Hypotensive265,266 (l) Anticonversant267
(m) Anti-HIV activity268,269 (n) Antineoplastic activity270
(o) Antidiabetic activity271 (p) Aspartyl protease inhibitor272
(q) Mycobacterial agents273-276
167Studies on pyrimidinyl sulphonamides...
OTHER CHEMOTHERAPEUTIC APPLICATION OF SULPHONAMIDES
Clinical observations on the earlier sulphonamides showed that some
members had diuretic properties. The earlier sulphonamides , particularly those
not having substitutents on the amide nitrogen, were shown not to behave sodi-
um channel blocking agents such as triamterene (67) and amiloride (68)  or


















The sulphonamide known as methazolamide (70)  is particularly useful in
the treatment of glaucoma, it is rather lipophilic and tends to concentrate in the













There is one other area where sulphonamide derivatives have found clini-
cal applications and that is in the treatment of noninsulin dependent diabetes.
The sulphonamides used contain the sulphonylurea side chain, such as tolb-
utamide (71) and glipizide (72) . The studies on these agents show that they do
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R = alkyl, aryl,heteroaryl
N. Furusawa278  has synthesized sulphonamides (74)  and reported anti-








Recently, H. Peyman et.al.,279 have reported aryl sulphonamides as
vitronectin receptor antagonists . F. Walter et.al., B. Volker et.al., and Y. Isao et.
al.,280,281-282  have prepared heteroaromatic sulphonamides (75)  as endo-

















169Studies on pyrimidinyl sulphonamides...
STRUCTURE-ACTIVITY STUDIES ON SULPHONAMIDES
In order to unravel this complex set of parameters the problem is often divided
into parts: an examination of the efficacy of a potential drug in cell free system, fol-
lowed by studies on intact cell and then studies in animal and finally, clinical stud-
ies in man. An important aim of studies on structure-activity relationship (SAR) is
to try to establish quantitative expressions (QSAR) relating chemical structure to
physicochemical properties of a group of drugs. The overall relationship between
dosing and effect may be devided in to three separate steps, the pharmaceutical,
pharmacokinetic and pharmacodynamic processes. In general two types of physi-
cochemical conditions are necessary for biological action: (1) Chemical proper-
ties necessary to induce a physicochemical or chemical reaction at the receptor
site; and (2) physicochemical properties which determine the pharmacokinetics
of the drug.i.e absorption, distribution, metabolism, binding to nonspecific binding
sites and excretion with respect to the biological system involved.
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on sulphonamides for their various method of synthesis and
different pharmacological activities, synthesis of pyrimidinyl sulphonamides
have been undertaken which can be summarized as under.
SECTION - I       : PREPARATION AND BIOLOGICAL SCREENING OF 2-MERCAP-
TO- 4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-ARYL-
-1,6-DIHYDROPYRIMIDINES.
SECTION - II      : PREPARATION AND BIOLOGICAL SCREENING OF 2-METHYL-
THIO-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-
ARYL-1,6-DI HYDROPYRIMIDINES .
SECTION - III     : PREPARATION AND BIOLOGICAL SCREENING OF 2-METHYL-
SULPHONYL-4-(p-AMINOPHENYLSULPHONYL AMINO)-5-CY-
ANO-6-ARYLPYRIMIDINES .
SECTION - IV     : PREPARATION AND BIOLOGICAL SCREENING OF 2-HYDRA-
ZINO-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-
ARYL-1,6-DIHYDROPYRIMIDINES.
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SECTION - V      :   PREPARATION AND BIOLOGICAL SCREENING OF 2-[(2’,4’-DI-
          NITROPHENYL)THIO]-4-(p-AMINOPHENYLSULPHONYLAMINO)-
          5-CYANO-6-ARYL-1,6-DIHYDROPYRIMIDINES.
SECTION - VI     : PREPARATION AND BIOLOGICAL 2-[(2’,4’-DINITROPHENYL)-
          SULPHONYL]-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-
CYANO-6-ARYLPYRIMIDINES.
SECTION - VII    : PREPARATION AND BIOLOGICAL SCREENING OF 2-MERC-
APTO-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBO-
XAMIDO-6-AR YLPYRIMIDINES .
SECTION - VIII   : PREPARATION AND BIOLOGICAL SCREENING OF 2-METH-
YLTHIO-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBOXA-
MIDO-6-ARYLPYRIMIDINES .
SECTION - IX     : PREPARATION AND BIOLOGICAL SCREENING OF 2-METH-
YLSULPHONYL-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-
CARBOXAMIDO- 6-ARYLPYRIMIDINES.
SECTION - X      :   PREPARATION AND BIOLOGICAL SCREENING OF 2-HYDRA-
ZINO-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBOXA-
MIDO-6-AR YLPYRIMIDINES .
SECTION - XI     :   PREPARATION AND BIOLOGICAL SCREENING OF 2-[(2’,4’-DI-
NITROPHENYL)THIO]-4-(p-AMINOPHENYLSULPHONYLAMINO)-
5-CARBOXAMIDO-6-ARYLPYRIMIDINES .
SECTION - XII    : PREPARATION AND BIOLOGICAL SCREENING OF 2-[(2’,4’-DI-
NITROPHENYL)SULPHONYL]-4-(p-AMINOPHENYLSULPHONYL-
AMINO)-5-CARBOXAMIDO-6-ARYLPYRIMIDINES .
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SECTION - I
PREPARATION AND BIOLOGICAL SCREENING OF 2-MERCAPTO-4-
(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-ARYL-1,6-DIHYDRO-
PYRIMIDINES.
Keeping in view the interesting properties223-243  and pharmacologi-
cal activities244-283  of sulphonamides , it has been revealed that sulphona-
mides are valuable drugs for various diseases and for viral diseases. These ob-
servation led us to synthesis of some novel 2-mercapto-4-(p-aminophenylsul-
phonyl-amino)-5-cyano-6-aryl-1,6-dihydropyrimidines (k1-8) have been un-
dertaken by the condensation of different 2-mercapto-4-amino-5-cyano-6-aryl-
1,6-dihydropyrimidines with p-acetamidophenylsulphonylchloride  in pres-









The constitution of the products (k1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (k1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized compounds
were compared wi th  s tandard drugs viz. Ampicillin , Chloramphenicol,
Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(k1-8)       R=Aryl
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   Internal Standard : TMS ; Solvent ; CDCl3 ;Instrument : BRUKER Spectrometer
   (300 MHz)


















































































































































































m/z = 376 
m/z = 360 (M+2)
m/z = 347 (M+1) (BP)
m/z = 331 (M+2)
m/z = 303
m/z = 277 (M-2)
m/z = 263 (M-2)
m/z = 249(M-2)m/z = 236
m/z = 133(M-2)
m/z = 120 (M-1)
m/z = 106 (M-2)
m/z = 92 (M-1)
m/z = 77
m/z = 415 (M+1)
(k5)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-MERCAPTO-4-
(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-ARYL-1,6-DIHYDRO-
PYRIMIDINES.
(A) Preparation of 2-mercapto-4-amino-5-cyano-6-(4’-methoxyphenyl)-
1,6-dihydropyrimidine (Ie).
A mixture of p-methoxybenzaldehyde  (1.36 ml, 0.01 M), malononitrile
(0.66 ml, 0.01 M), thiourea (0.76 gm, 0.01 M) and con. HCl (3 ml) in ethanol (30
ml) was heated under refluxed condition for 4 hrs. Then the reaction mixture was
kept at room temperature for 2 hrs. The yellow crystalline product was obtained.
The product was isolated and recrystallized from ethanol. Yield : 70%, M.P. : 122°C,
Rf
1
: 0.41, R f
2
 : 0.56 (Required : C, 55.38%; H, 4.62%; N, 21.54% for C 12H12N4OS,
Found : C, 55.32% ; H, 4.58%; N, 21.50%).
Similarly, other compounds  (Ia-h ) were synthesized. The physical data
are recorded in Table No. 11.
(B) Preparation of 2-mercapto-4-(p-acetamidophenylsulphonylamino)-
5-cyano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine (IIe).
A mixture of 2-mercapto-4-amino-5-cyano-6-(4’-methoxyphenyl)-1,6-
dihydropyrimidine  (2.60 gm, 0.01 M) and p-acetamidophenylsulphonylchlo-
ride (2.33 gm, 0.01 M) in pyridine (15 ml) was heated under refluxed condition
for 12 hrs. Then the reaction mixture was poured into crushed ice. The product so
obtained was recrystallized from ethanol. Yield : 71%, M.P. : 176°C, R f
1
: 0.42, R f
2
: 0.61  (Required : C, 52.52%; H, 4.16%; N, 15.32% for C 20H19N5O4S2, Found
: C, 52.48% ; H, 4.11%; N, 15.27%).
Similarly, other compounds  (Ila-h ) were synthesized. The physical data
are recorded in Table No. 11a.
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(C) Preparation of 2-mercapto-4-(p-aminophenylsulphonylamino)-5-
cyano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine (k5).
A mixture of 2-mercapto-4-(p-acetamidophenylsulphonylamino)-5-cy-
ano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine  (4.57 gm, 0.01 M) and con.
HCl (4 ml) in ethanol (25 ml) was heated under refluxed condition for 6 hrs. Then
the reaction mixture was poured into crushed ice. The product so obtained was
recrystallized from ethanol. Yield : 72%, M.P. : 162°C, Rf
1
 : 0.49, Rf
2
 : 0.63 (Re-
quired : C: 52.05%; H: 4.10%;   N: 16.87% for C18H17N5O3S2, Found : C: 52.01%;
H: 4.06%; N: 16.82% ).
Similarly, other compounds  (k1-8) were synthesized. The  physical data
are recorded in Table No. 11b .
(D) Antimicrobial activity of 2-mercapto-4-(p-aminophenylsulphonyl-
amino)-5-cyano-6-aryl-1,6-dihydropyrimidines (k1-8).
Antimicrobial activity testing was carried out as described in part-I, section-
I, page No. 33. The zone of inhibition of test solution are recorded in Table No.11c,
11d & 11e.
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SECTION - II
PREPARATION AND BIOLOGICAL SCREENING OF 2-METHYLTHIO-
4-(p-AMINOPHENYLSULPHONYLAMINO) -5 -C YANO-6-ARYL-1,6-DI-
HYDROPYRIMIDINES .
Keeping in view the interesting properties223-243  and pharmacologi-
cal activities243-283  of sulphonamides , it has been revealed that sulphona-
mides are valuable drugs for various diseases and for viral diseases. These ob-
servation led us to synthesis of some novel 2-methylthio-4-(p-aminophenylsul-
phonylamino)-5-cyano-6-aryl-1,6-dihydropyrimidines  (l1-8) have been under-
taken by the condensation of different 2-methylthio-4-amino-5-cyano-6-aryl-
1,6-dihydropyrimidines with p-acetamidophenylsulphonylchloride in presence









The constitution of the products (l1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (l1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(l1-8)         R=Aryl
















2975  - 2900
2880  - 2860
1460  - 1435
1385  - 1300
1520  - 1480
1580  - 1520
3080  - 3030
1125  - 1090
  840 -  810
3500  - 3310
1650  - 1580
1275  - 1200
1075  - 1050
1180  - 1140
1380  - 1300
1180  - 1140
2260  - 2190
700  - 600
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 Internal Standard : TMS ; Solvent ; CDCl3; Instrument : BRUKER Spectrometer (300 MHz)






















































































































































































m/z = 397 (M-1)
m/z = 370(M+1) m/z = 353 (M-2)
m/z = 77
m/z = 325
m/z = 92 (M-1)
m/z = 311 (M-1)
m/z = 429
m/z = 120 (M+1)
m/z = 135 (M-1)
m/z = 295 (BP)
m/z = 148 (M-1) m/z = 160 (M+1) m/z = 175
m/z = 205
m/z = 283 (M-1)
(l5)
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REACTION SCHEME











































191Studies on pyrimidinyl sulphonamides...
EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-METHYLTHIO-4-
(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-ARYL-1,6-DIHYDROPY-
RIMIDINES .
(A) Preparation of 2-mercapto-4-amino-5-cyano-6-(4’-methoxyphenyl)-1,
6-dihydropyrimidine (Ie).
For preparation refer Part-IIB, Section-I, Page No.177.
(B) Preparation of 2-methylthio-4-amino-5-cyano-6-(4’-methoxyphenyl)-
1,6-dihydropyrimidine (IIIe).
A mixture of 2-mercapto-4-amino-5-cyano-6-(4’-methoxyphenyl)-1,6-
dihydropyrimidine (2.60 gm, 0.01 M), dimethyl sulphate (1.26 ml, 0.01 M) in
ethanol (30 ml) and 40% aq. NaOH  (2.0 ml) was stirred for 12 hrs. at room tem-
perature. The content was poured into ice cold water and filtered. The product





 : 0.63 (Required :C: 56.93%; H: 5.11%; N: 20.44% for C13H14N4OS, Found :
C: 56.88%; H: 5.07%; N: 20.40% ).
Similarly, other compounds  (lIIa-h ) were synthesized. The physical data
are recorded in Table No. 12.
(C) Preparation of 2-methylthio-4-(p-acetamidophenylsulphonylamino)-
5-cyano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine (IV e).
A mixture of 2-methylthio-4-amino-5-cyano-6-(4’-methoxyphenyl)-1,6-
dihydropyrimidine  (2.74 gm, 0.01 M) and p-acetamidophenylsulphonylchlo-
ride (2.33 gm, 0.01 M) in pyridine (15 ml) was heated under refluxed condition
for 12 hrs. Then the reaction mixture was poured into crushed ice. The  product so





 : 0.72 (Required :C: 53.50%; H: 4.46%; N: 14.86% for C21H21N5O4S2, Found
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: C: 53.45%; H: 4.42%; N: 14.82% ).
Similarly, other compounds  (lVa-h) were synthesized. The physical data
are recorded in Table No. 12a.
(D) Preparation of 2-methylthio-4-(p-aminophenylsulphonylamino)-5-cy-
ano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine (l5).
A mixture of 2-methylthio-4-(p-acetamidophenylsulphonylamino)-5-cy-
ano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine  (4.71 gm, 0.01 M) and con.
HCl (4 ml) in ethanol (25 ml) was heated under refluxed condition for 6 hrs. Then
the reaction mixture was poured into crushed ice. The  product so obtained  was





 : 0.64 (Required :C: 53.15%; H: 4.43%; N: 16.32% for C19H19N5O3S2, Found
: C: 53.11%; H: 4.39%; N: 16.26% ).
Similarly, other compounds  (l1-8) were synthesized. The physical data
are recorded in Table No. 12b.
(E) Antimicrobial activity of 2-methylthio-4-(p-aminophenylsulphonyl-
amino)-5-cyano-6-aryl-1,6-dihydropyrimidines (l1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table
No. 12c, 12d & 12e.
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SECTION - III
PREPARATION AND BIOLOGICAL SCREENING OF 2-METHYL -
SULPHONYL-4- (p -AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-
ARYLPYRIMIDINES .
Keeping in view the interesting properties223-243  and pharmacologi-
cal activities244-283  of sulphonamides , it has been revealed that sulphona-
mides are valuable drugs for various diseases and for viral diseases. These ob-
servation led us to synthesis of some novel 2-methylsulphonyl-4-(p-aminophe-
nylsulphonylamino)-5-cyano-6-arylpyrimidines (m1-8) have been undertaken
by the condensation of different 2-methylsulphonyl-4-amino-5-cyano-6-aryl-
1,6-dihydropyrimidines with p-acetamidophenylsulphonyl chloride in presence











The constitution of the products (m1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (m1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(m1-8)             R=Aryl
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Internal Standard : TMS ; Solvent ; CDCl3, CHCl3; Instrument : BRUKER Spectrometer
(300 MHz)

















































































































































































































m/z = 106 (M-2)
m/z = 459 (M+2) (BP)
m/z = 133
m/z = 389 (M-2)
m/z = 311
m/z = 148 m/z = 293 (M
+2)
m/z = 158 (M+2)
m/z = 173 (M+1) m/z = 234 (M
+1) m/z = 255 (M
+1)
m/z = 267 (M+1)
+
(m5)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2 - M E T H Y L
SULPHONYL-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-ARYL-
PYRIMIDINES .
(A) Preparation of 2-methylthio-4-amino-5-cyano-6-(4’-methoxyphenyl)-
1,6-dihydropyrimidine (IIIe).
For preparation refer Part-IIB, Section-II, Page No. 191.
(B) Preparation of 2-methylsulphonyl-4-amino-5-cyano-6-(4’-methoxyph-
enyl)pyrimidine (Ve).
A mixture of 2-methylthio-4-amino-5-cyano-6-(4’-methoxyphenyl)-1,6-
dihydropyrimidine  (2.74 gm, 0.01 M) was dissolved in 20ml of gla. acetic acid
and add 12 ml of hydrogen peroxide  and then kept for 48 hrs. at room tempera-
ture. The content was poured into ice cold water and filtered. The product was
isolated and crystallized from ethanol. Yield : 60%, M.P. : 94°C, Rf
1
 : 0.67, Rf
2
 :
0.59 (Required : C: 51.32%; H: 3.95%; N: 18.42% for C13H12N4O3S, Found : C:
51.28%; H: 3.91%; N: 18.37% ).
Dilute solution of H2O2 in acetic acid will result into oxidation of methylthio
(-SCH3) group only lead to formation of methylsulphonyl (-SO2CH3) deriva-
tives.  From the spectral data of IR  and Mass indicates that there is no oxidation
of the cyclic nitrogen of the pyrimidine  to nitroso (-NO)  and there is no refer-
ences quoted in this regards at lower concentration of H2O2 in gl. acetic acid .
Similarly, other compounds  (Va-h) were synthesized. The physical data
are recorded in Table No.13.
(C ) Preparation of 2-methylsulphonyl-4-(p-acetamidophenylsulphonyl-
amino)-5-cyano-6-(4’-methoxyphenyl)pyrimidine (VIe).
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A mixture of 2-methylsulphonyl-4-amino-5-cyano-6-(4’-methoxyph-
enyl)pyrimidine  (3.04 gm, 0.01 M) and p-acetamidophenylsulphonylchloride
(2.33 gm, 0.01 M) in pyridine (15 ml) was heated under refluxed condition for 12
hrs. Then the reaction mixture was poured into crushed ice. The product so ob-
tained  was recrystallized from ethanol. Yield : 72%, M.P. : 124°C, Rf
1
 : 0.35, Rf
2
 :
0.54 (Required : C: 50.30%; H: 3.79%; N: 13.97% for C21H19N5O6S2, Found : C:
50.26%; H: 3.75%; N: 13.92%).
Similarly, other compounds  (VIa-h) were synthesized. The physical data
are recorded in Table No.13a.
(D) Preparation of 2-methylsulphonyl-4-(p-aminophenylsulphonylamino)-
5-cyano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine (m5).
A mixture of 2-methylsulphonyl-4-(p-acetamidophenylsulphonylamino)-
-5-cyano-6-(4’-methoxyphenyl)pyrimidine  (5.01 gm, 0.01 M) and con. HCl (4
ml) in methanol (25 ml) was heated under refluxed condition for 6 hrs. Then the
reaction mixture was poured into crushed ice. The product so obtained was re-





 : 0.59 (Required : C: 49.67%; H: 3.70%; N: 15.25% for C19H17N5O5S2, Found
: C: 49.62%; H: 3.66%; N: 15.20% ).
Similarly, other compounds  (m1-8) were synthesized. The physical data
are recorded in Table No.13b.
(E) Antimicrobial activity of 2-methylsulphonyl-4-(p-aminophenylsulpho-
nylamino)-5-cyano-6-arylpyrimidines (m1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table
No. 13c, 13d & 13e.
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SECTION - IV
PREPARATION AND BIOLOGICAL SCREENING OF 2-HYDRAZINO-4-
(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-ARYL-1,6-DIHYDROPY-
RIMIDINES .
Keeping in view the interesting properties223-243  and pharmacologi-
cal activities244-283  of sulphonamides , it has been revealed that sulphona-
mides are valuable drugs for various diseases and for viral diseases. These ob-
servation led us to synthesis of some novel 2-hydrazino-4-(p-aminophenylsul-
phonylamino)-5-cyano-6-aryl-1,6-dihydropyrimidines  (n1-8) have been under-
taken by the condensation of different 2-methylthio-4-(p-aminophenylsul-









The constitution of the products (n1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (n1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(n1-8)      R=Aryl
214Studies on pyrimidinyl sulphonamides...
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PMR SPECTRAL STUDY OF  2-HYDRAZINO-4-(p-AMINOPHENYLSULPHO-












































  Internal Standard : TMS ; Solvent ; CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)






















































































































































m/z = 400 (M+1)
m/z = 369 (M+1)
m/z = 342 (M-2)














































m/z = 175 (M-2) (BP)
NH2
NH2NH2
m/z = 163 (M-2)
NH
NH2





m/z = 104 (M-2)
+
m/z = 91 (M-2)
(n5)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-HYDRAZINO-
4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-ARYL-1,6-DIHYDRO-
PYRIMIDINES .
(A) Preparation of 2-methylthio-4-(p-aminophenylsulphonylamino)-5-cy-
ano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine (l5).
For preparation refer Part - IIB, Section - II, Page No. 192.
(B) Preparation of 2-hydrazino-4-(p-aminophenylsulphonylamino)-5-
cyano-6- (4’-methoxyphenyl)-1,6-dihydropyrimidine (n5).
A mixture of 2-methylthio-4-(p-aminophenylsulphonylamino)-5-cyano-
6-(4’-methoxyphenyl)-1,6-dihydropyrimidine (2.78 gm, 0.01 M) and hydrazine
hydrate  (1.0 ml, 0.02M) in ethanol (30 ml) was heated under reflux condition for
five hrs. The content was poured into ice cold water and filtered. The product was
isolated and crystallized from methanol:dioxane(1:3) . Yield : 62%, M.P. : 172°C,
Rf
1
: 0.47, R f
2
: 0.54 (Required : C: 52.30%; H: 4.60%; N: 23.73% for C18H19N7O3S,
Found : C: 52.26%; H: 4.56%; N: 23.66% ).
Similarly, other compounds  (n1-8) were synthesized. The physical data
are recorded in Table No. 14.
(C) Antimicrobial activity of 2-hydrazino-4-(p-aminophenylsulphonyl-
amino)-5-cyano-6-aryl-1,6-dihydropyrimidines (n1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table
No. 14a, 14b & 14c.
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SECTION - V
PREPARATION AND BIOLOGICAL  SCREENING OF 2-[(2’,4’-DINITRO-
PHENYL)THIO]-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-ARYL-
1,6-DIHYDROPYRIMIDINES.
Keeping in view the interesting properies223-243  and pharmacologi-
cal activities244-283  of sulphonamides , it has been revealed that sulphona-
mides are valuable drugs for various diseases and for viral diseases. These ob-
servation led us to synthesis of some novel 2-[(2’,4’-dinitrophenyl)thio ]-4-(p-
amin ophenylsulphonylamino)-5-cyano-6-aryl-1,6-dihydropyrimidines(o1-8)
have been undertaken by the condensation of different 2-[(2’,4’-dinitrophen-
yl)thio]-4-amino-5-cyano-6-aryl-1,6-dihydropyrimidines with p-acetamido-












The constitution of the products (o1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (o1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(o1-8)    R=Aryl
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   Internal Standard : TMS ; Solvent ; CDCl3, DMSO; Instrument : BRUKER Spectrometer
   (300 MHz)

































































































































































































































m/z = 221  (M+2)
NH2
CH2
m/z = 133 (M -1)
CH3
m/z = 92 (M -1)
m/z = 77
m/z = 551 (M+1)
+
(o1)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-[(2’,4’-DINITRO-
PHENYL)THIO]-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-6-ARYL-
1,6-DIHYDROPYRIMIDINES.
(A) Preparation of 2-mercapto-4-amino-5-cyano-6-(4’-methoxyphenyl)-
1,6-dihydropyrimidine (Ie).
For preparation refer Part-IIB, Section-I, Page No.177.
(B) Preparation of 2-[(2 ’,4 ’-dinitrophenyl)thio]-4-amino -5-cyano-6-
(4’-methoxyphenyl)-1,6-d ihydropyrimidine (VIIe).
A mixture of 2-mercapto-4-amino-5- cyano-6-(4’-methoxyphenyl)-1,6-
dihydropyrimidine  (2.60 gm, 0.01 M) and 1-chloro-2,4-dinitrobenzene  (2.02
gm, 0.01 M) in ethanol (30 ml) and add 2 ml of 10% aq. sodium hydroxide
was heated under refluxed condition for three hrs. The content was poured into
ice cold water and filtered. The product was isolated and crystallized from etha-




: 0.67 (Required : C: 50.70%; H:
3.29%; N: 19.72% for C18H14N6O5S, Found : C: 50.66%; H: 3.25%; N:19.68% ).
Similarly, other compounds  (VIIa-h) were synthesized. The physical data
are recorded in Table No.15.
(C) Preparation of 2-[(2 ’,4 ’-dinitrophenyl)thio]-4-(p-acetamidophenyl-
sulphonylamino)-5-cyano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine
(VIIIe).
A mixture of 2-[(2’,4’-dinitrophenyl)thio]-4-amino-5-cyano-6-(4’-metho-
xyphenyl)-1,6-dihydropyrimidine  (4.26 gm, 0.01 M) and p-acetamidophenyl-
sulphonylchloride  (2.33 gm, 0.01 M) in pyridine (15 ml) was heated under refl-
uxed condition for 12 hrs. Then the reaction mixture was poured into crushed ice.
The product so obtained was recrystallized from ethanol:dioxane(1:2). Yield
231Studies on pyrimidinyl sulphonamides...




: 0.50 (Required : C: 50.08%; H: 3.37%; N:
15.73% for C26H21N7O8S2, Found : C: 50.04%; H: 3.32%; N:15.69% ).
Similarly, other compounds  (VIIIa-h) were synthesized. The physical data
are recorded in Table No.15a.
(D) Preparation of 2-[(2 ’,4 ’-dinitrophenyl)thio]-4-(p-aminophenylsulph-
onylamino)-5-cyano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine (o5).
A mixture of 2-[(2’,4’-dinitrophenyl)thio]-4-(p-acetamidophenylsulpho-
nylamino)-5-cyano-6-(4’-methoxyphenyl)-1,6-dihydropyrimidine (6.23 gm,
0.01 M) and con. HCl (4 ml) in ethanol (25 ml) was heated under refluxed condi-
tion for 6 hrs. Then the reaction mixture was poured into crushed ice. The product





: 0.67 (Required : C: 49.57%; H: 3.27%; N: 16.87% for
C24H19N7O7S2, Found : C: 49.53%; H: 3.23%; N:16.80% ).
Similarly, other compounds  (o1-8) were synthesized. The physical data
are recorded in Table No.15b.
(E) Antimicrobial activity of 2-[(2’,4’-dinitrophenyl)thio]-4-(p-aminophenyl-
sulphonylamino)-5-cyano-6-aryl-1,6-dihydropyrimidines (o1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table
No. 15c, 15d & 15e.
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SECTION - VI
PREPARATION AND BIOLOGICAL SCREENING OF 2-[(2’,4’-DINITRO-
PHENYL)SULPHONYL]-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-
6-ARYLPYRIMIDINES .
Keeping in view the interesting properties223-243  and pharmacologi-
cal activities 244-283of sulphonamides , it has been revealed that sulphona-
mides are valuable drugs for various diseases and for viral diseases. These
observation led us to synthesis of some novel 2-[(2’,4’-dinitrophenyl)sulphonyl]-
4-(p-aminophenylsulphonylamino)-5-cyano-6-arylpyrimidines (p1-8) have
been undertaken by the condensation of different 2-[(2’,4’-dinitrophenyl)sulpho-
nyl]-4-amino-5-cyano-6-arylpyrimidines with p-acetamidophenylsulphonyl-













The constitution of the products (p1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (p1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(p1-8) R=Aryl
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  Internal Standard : TMS ; Solvent ; CDCl3 ;Instrument : BRUKER Spectrometer (300 MHz)














































































































































































m/z = 219(M+2) 
NH2
CH2
m/z = 133 (M -1)
CH3
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-[(2’,4’-DINITRO-
PHENYL)SULPHONYL]-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CYANO-
6-ARYLPYRIMIDINES .
(A) Preparation of 2-[(2’,4’-dinitrophenyl)thio]-4-amino-5-cyano-6-(4’-me-
thoxyphenyl)-1,6-d ihydropyrimidine (VIIe).
For preparation refer Part-IIB, Section-V, Page No. 230.
(B) Preparation of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-amino-5-cyano-6-
(4’-methoxyphenyl)pyrimidine (IXe).
A mixture of 2-[(2’,4’-dinitrophenyl)thio]-4-amino-5-cyano-6-(4’-metho-
xyphenyl)-1,6-dihydropyrimidine  (4.26 gm, 0.01 M) was dissolved in 20ml of
gla. acetic acid  and add 12 ml of hydrogen peroxide  and then kept for 48 hrs.
at room temperature. The content was poured into ice cold water and filtered. The
product was isolated and crystallized from ethanol:dioxane(1:1) . Yield : 60%,
M.P. : 208°C, Rf
1
 : 0.58, Rf
2
 : 0.63 (Required : C: 47.37%; H: 2.63%; N: 18.42% for
C18H12N6O7S, Found : C: 47.33%;   H: 2.68%; N:18.38% ).
Similarly, other compounds  (IXa-h) were synthesized. The physical data
are recorded in Table No.16.
(C) Preparation of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-(p-acetamidophenyl-
sulphonylamino)-5-cyano-6-(4’-methoxyphenyl)pyrimidine (Xa-h).
A mixture of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-amino-5-cyano-6-(4’-
methoxyphenyl)pyrimidine  (4.56 gm, 0.01 M) and p-acetamidophenychloride
(2.33 gm, 0.01 M) in pyridine (15 ml) was heated under refluxed condition for
12 hrs. Then the reaction mixture was poured into crushed ice. The product so
obtained was recrystallized from methanol:DMF(1:2) . Yield : 78%, M.P. : 212°C,
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Rf
1
 : 0.41, Rf
2
 : 0.61 (Required : C: 47.78%; H: 2.91%; N: 15.01% for C26H19N7O10S2,
Found : C: 47.73%;   H: 2.87%; N:14.97% ).
Similarly, other compounds  (Xa-h) were synthesized. The physical data
are recorded in Table No.16a.
(D) Preparation of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-(p-aminophenyl-
sulphonylamino)-5-cyano-6-(4’-methoxyphenyl)pyrimidine (p 5).
A mixture of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-(p-acetamidophenyl-
sulphonylamino)-5-cyano-6-(4’-methoxyphenyl)pyrimidine  (6.53 gm, 0.01 M)
and con.HCl (4 ml) in methanol (25 ml) was heated under refluxed condition for
6 hrs. Then the reaction mixture was poured into crushed ice. The product so ob-





 : 0.64 (Required : C: 47.14%; H: 2.78%; N: 16.04% for C24H17N7O9S2,
Found : C: 47.10%;   H: 2.73%; N:16.00% ).
Similarly, other compounds  (p1-8) were synthesized. The physical data
are recorded in Table No.16b.
(E) Antimicrobial activity of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-(p-amino-
phenylsulphonylamino)-5-cyano-6-arylpyrimidines (p1-8).
Antimicrobial activity testing was carried out as described in part-1,
section-1, page No. 33 . The zone of inhibition of test solution are recorded in
Table No. 16c, 16d & 16e.
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SECTION - VII
PREPARATION AND BIOLOGICAL SCREENING OF 2-MERCAPTO-4-
(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYLPYRIMI-
DINES.
Keeping in view the interesting properties223-243  and pharmacologi-
cal activities244-283of sulphonamides , it has been revealed that sulphona-
mides are valuable drugs for various diseases and for viral diseases. These
observation led us to synthesis of some novel 2-mercapto-4-(p-aminophenyl-
sulphonylamino)-5-carboxamido-6-arylpyrimidines  (q1-8) have been under-
taken by the condensation of different 2-mercapto-4-amino-5-carboxamido-6-
arylpyrimidines  with p-acetamidophenylsulphonylchloride in presence of











The constitution of the products (q1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (q1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(q1-8)        R=Aryl
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   Internal Standard : TMS; Solvent : CDCl3, DMSO; Instrument : BRUKER Spectrom-
   eter (300 MHz)




























































































































































m/z = 373 m/z = 357  (M-2)
m/z = 327 
m/z = 313
m/z = 297  (M -1)
m/z = 273  (M+1)m/z = 247  (M -1)m/z = 231m/z = 221
m/z = 143 (M -1)
m/z = 113 (M+2)
m/z = 106 (M-2)
m/z = 77
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-MERCAPTO-4-
(p -AMINOPHENYLSULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYLPYRI-
MIDINES .
(A) Preparation of 2-mercapto-4-amino-5-cyano-6-(4’-methoxyphenyl)-
1,6-dihydropyrimidine (Ie).
For preparation refer Part-IIB, Section-I, Page No. 177.
(B) Preparation of 2-mercapto-4-amino-5-carboxamido-6-(4’-methoxy-
phenyl)pyrimidine (XIe).
A mixture of 2-mercapto-4-amino-5-cyano-6-(4’-methoxyphenyl)-1,6-di-
hydropyrimidine  (0.01 M) was dissolved in conc. sulphuric acid  (20ml) below
5
o C and kept for 48 hrs. at room temperature. The content was poured into ice
cold water and filtered. The product was isolated and crystallized from ethanol.
Yield : 48%, M.P. : 140°C, Rf
1
 : 0.58, Rf
2
 : 0.63 (Required : C: 52.17%; H: 4.35%;
N: 20.29% for C12H12N4O2S, Found : C: 52.12%; H: 4.31%; N:20.25% ).
Similarly, other compounds  (XIa-h) were synthesized. The physical data
are recorded in Table No. 17.
(C) Preparation of 2-mercapto-4-(p-acetamidophenylsulphonylamino)-
5-carboxamido-6-(4’-methoxyphenyl)pyrimidine (XIIe).
A mixture of 2-mercapto-4-amino-5-carboxamido-6-(4’-methoxy-
phenyl)pyrimidine (2.76 gm, 0.01 M) and  p-acetamidophenylsul phonylchlo-
ride (2.33 gm, 0.01M) in pyridine (15 ml) was heated under refluxed condition for
12 hrs. Then the reaction mixture was poured into crushed ice. The product so





 : 0.64 (Required : C: 45.67%; H: 3.59%; N: 14.80% for C20H19N5O5S2, Found
: C: 45.62%; H: 3.55%; N:14.76% ).
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Similarly, other compounds  (XIIa-h) were synthesized. The physical data
are recorded in Table No. 17a .
(D) Preparation of 2-mercapto-4-(p-aminophenylsulphonylamino)-5-car -
boxamido-6-(4’-methoxyphenyl)pyrimidine (q 5).
A mixture of 2-mercapto-4-(p-acetamidophenylsulphonylamino)-5-car-
boxamido-6-(4’-methoxyphenyl)pyrimidine  (4.73 gm, 0.01 M) and con. HCl
(4 ml) in methanol (25 ml) was heated under refluxed condition for 6 hrs. Then the
reaction mixture was poured into crushed ice. The product so obtained was recry-
stallized from ethanol. Yield : 59%, M.P. : 108°C, Rf
1
 : 0.59, R f
2
 : 0.64 (Required :
C: 50.12%; H: 3.94%; N: 16.24% for C18H17N5O4S2, Found : C: 50.08%;   H:
3.90%; N:16.20% ).
Similarly, other compounds  (q1-8) were synthesized. The physical data
are recorded in Table No. 17b .
(E) Antimicrobial activity of 2-mercapto-4-(p-aminophenylsulphonyl-
amino)-5-carboxamido-6-arylpyrimidines (q1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table
No. 17c, 17d & 17e.
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SECTION - VIII
PREPARATION AND BIOLOGICAL SCREENING OF 2-METHYLTHIO-
4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYLPYRI-
MIDINES .
Keeping in view the interesting properties223-243  and pharmacologi-
cal activities244-283  of sulphonamides , it has been revealed that sulphona-
mides are valuable drugs for various diseases and for viral diseases. These ob-
servation led us to synthesis of some novel 2-methylthio-4-(p-aminophenyl-
sulphonylamino)-5-carboxamido-6-a ry lpyrimidines(r1-8) have been un-
dertaken by the condensation of different 2-methylthio-4-amino-5-carboxami-
do-6-aryl- pyrimidines with p-acetamidophenylsulphonylchloride  in presence










The constitution of the products (r1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (r1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(r1-8)       R=Aryl
267Studies on pyrimidinyl sulphonamides...
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   Internal Standard : TMS; Solvent : CDCl3, CHCl3; Instrument : BRUKER Spectrom-
   eter (300 MHz)
































































































































m/z = 404 (M+1)
















































m/z = 106 (M+2)






m/z = 70 (M-1)
(r5)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-METHYLTHIO-4-
(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYLPYRIMI-
DINES.
(A) Preparation of 2-methylthio-4-amino-5-cyano-6-(4’-methoxyphenyl)-
1,6-dihydropyrimidine (IIIe).
For preparation refer Part-IIB, Section-II, Page No.191.
(B) Preparation of 2-methylthio-4-amino-5-carboxamido-6-(4’-methoxy-
phenyl)pyrimidine (XIIIe).
A mixture of 2-methylthio-4-amino-5-cyano-6-(4’-methoxyphenyl)-1,6-
dihydropyrimidine  (2.74 gm, 0.01 M) was dissolved in conc. sulphuric acid
(20 ml) below 5
o
C and kept for 48 hrs. at room temperature. The content was
poured into ice cold water and filtered. The product was isolated and crystallized
from ethanol. Yield : 56%, M.P. : 185°C, Rf
1
 : 0.54, Rf
2
 : 0.61 (Required : C:
53.79%; H: 4.83%; N: 19.31% for C13H14N4O2S, Found : C: 53.75%; H: 4.78%;
N:19.27% ).
Similarly, other compounds  (XIIIa-h) were synthesized. The physical data
are recorded in Table No. 18.
(C) Preparation of 2-methylthio-4-(p-acetamidophenylsulphonylamino)-
5-carboxamido-6- (4’-methoxyphenyl)pyrimidine (XIVe).
A mixture of 2-methylthio-4-amino-5-carboxamido-6-(4’-methoxyphe-
nyl)pyrimidine (2.90 gm, 0.01 M) and  p-acetamidophenylsulphonylchloride
(2.33 gm, 0.01M) in pyridine (15 ml) was heated under refluxed condition for 12
hrs. Then the reaction mixture was poured into crushed ice. The  product  so ob-
tained  was recrystallized from ethanol. Yield : 53%, M.P. : 210°C, Rf
1
 : 0.51, Rf
2
: 0.74 (Required : C: 51.74%; H: 4.31%; N: 14.37% for C21H21N5O5S2, Found :
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C: 51.69%; H: 4.27%; N:14.32% ).
Similarly, other compounds  (XIVa-h) were synthesized. The physical data
are recorded in Table No. 18a .
(D) Preparation of 2-methylthio-4-(p-aminophenylsulphonylamino)-5-car-
boxamido -6-(4’-methoxyphenyl)pyrimidine (r5).
A mixture of 2-methylthio-4-(p-acetamidophenylsulphonylamino)-5-
carboxamido-6-(4’-methoxyphenyl)pyrimidine  (4.87 gm, 0.01 M) and con. HCl
(4 ml) in methanol (25 ml) was heated under refluxed condition for 6 hrs. Then the
reaction mixture was poured into crushed ice. The  product so obtained was





 : 0.64 (Required : C: 51.24%; H: 4.27%; N: 15.73% for C19H19N5O4S2, Found
: C: 51.19%; H: 4.22%; N:15.70% ).
Similarly, other compounds  (r1-8) were synthesized. The physical data
are recorded in Table No. 18b .
(E) Antimicrobial activity of 2-methylthio-4-(p-aminophenylsulphonyl-
amino)-5-carboxamid o-6-a ry lpyrimidines (r1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table
No. 18c, 18d & 18e.
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SECTION - IX
PREPARATION AND BIOLOGICAL SCREENING OF 2-METHYLSU LPHO-
NYL-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYL-
PYRIMIDINES.
Keeping in view the interesting properies223-243  and pharmacological
activities244-283  of sulphonamides , it has been revealed that sulphonamides
are valuable drugs for various diseases and for viral diseases. These observation
led us to synthesis of some novel 2-methylsulphonyl-4-(p-aminophenylsulph-
onylamino)-5-carboxamido-6-arylpyrimidines  (s1-8) have been undertaken by
the condensation of different 2-methylsulphonyl-4-amino-5-carboxamido-6-
arylpyrimidines with p-acetamidophenylsulphonylchloride  in presence of py-














The constitution of the products (s1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (s1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized compounds
were compared wi th  s tandard drugs viz. Ampicillin , Chloramphenicol,
Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(s1-8)           R=Aryl
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   Internal Standard : TMS; Solvent : CDCl3, CHCl3; Instrument : BRUKER Spectrom-
   eter (300 MHz)































































































































































































m/z = 133 (M-1)
CH3
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-METHYL-
SULPHONYL-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBOXAMIDO- 6-
ARYLPYRIMIDINES .
(A) Preparation of 2-methylsulphonyl-4-amino-5-cyano-6-(4’-methoxyphe-
nyl)pyrimidine (V e).
For preparation refer Part-IIB, Section-III, Page No. 203.
(B) Preparation of 2-methylsulphonyl-4-amino-5-carboxamido-6-(4’-me-
thoxyphenyl)pyrimidine (XVe).
A mixture of 2-methylsulphonyl-4-amino-5-cyano-6-(4’-methoxyphe-
nyl)pyrimidine (3.04 gm, 0.01 M) was dissolved in conc. sulphuric acid  (20ml)
below 5
o
C and kept for 48 hrs. at room temperature. The content was poured into
ice cold water and filtered. The product was isolated and crystallized from etha-
nol. Yield : 59%, M.P. : 109°C, Rf
1
 : 0.50, Rf
2
 : 0.61 (Required : C: 48.45%; H:
4.35%; N: 17.39% for C13H14N4O4S, Found : C: 48.41%; H: 3.32%; N:17.34% ).
Similarly, other compounds  (XVa-h) were synthesized. The physical data
are recorded in Table No. 19.
(C) Preparation of 2-methylsulphonyl-4-(p-acetamidophenylsulphonyl-
amino)-5-carboxamido-6- (4’-methoxyphenyl)pyrimidine (XVIe).
A mixture of 2-methylsulphonyl-4-amino-5-carboxamido-6-(4’-methoxy-
phenyl)pyrimidine  (3.22 gm, 0.01 M) and p-acetamidophenylsulphonylchlo-
ride (2.33 gm, 0.01M) in pyridine (15 ml) was heated under refluxed condition for
12 hrs. Then the reaction mixture was poured into crushed ice. The  product  so
obtained  was recrystallized from methanol:DMF(2:1) . Yield : 73%, M.P. : 185°C,
Rf
1
 :  0.51, Rf
2
 :  0.69 (Required :  C: 48.55%; H: 4.05%; N: 13.48% for
C21H21N5O7S2, Found : C: 48.51%; H: 4.01%; N:13.43% ).
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Similarly, other compounds  (XVIa-h) were synthesized. The physical data
are recorded in Table No. 19a .
(D) Preparation of 2-methylsulphonyl-4-(p-aminophenylsulphonylamino)-
5-carboxamido -6-(4’-methoxyphenyl)pyrimidine (s5).
A mixture of 2-methylsulphonyl-4-(p-acetamidophenylsulphonyl-
amino)-5-carboxamido-6-(4’-methoxyphenyl)pyrimidine (5.19 gm, 0.01 M)
and con. HCl (4 ml) in methanol (25 ml) was heated under refluxed condition for
6 hrs. Then the reaction mixture was poured into crushed ice. The product so
obtained was recrystallized from methanol:DMF(1:1) . Yield : 50%, M.P. : 115°C,
Rf
1
 :  0.50, Rf
2
 :  0.63 (Required :  C: 47.80%; H: 3.98%; N: 14.67% for
C19H19N5O6S2, Found : C: 47.76%; H: 3.94%; N:14.61% ).
Similarly, other compounds  (s1-8) were synthesized. The physical data
are recorded in Table No. 19b .
(E) Antimicrobial activity of 2-methylsulphonyl-4-(p-aminophenylsulpho-
nylamino)-5-carboxamido-6- arylpyrimidines (s1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33. The zone of inhibition of test solution are recorded in Table
No. 19c, 19d & 19e.
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SECTION - X
PREPARATION AND BIOLOGICAL SCREENING OF 2-HYDRAZINO-4-
(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYLPYRIM-
IDINES .
Keeping in view the interesting properties223-243  and pharmacologi-
cal activities244-286  of sulphonamides , it has been revealed that sulphona-
mides are valuable drugs for various diseases and for viral diseases. These ob-
servation led us to synthesis of some novel 2-hydrazino-4-(p-aminophenylsul-
phonylamino)-5-carboxamido-6-arylpyrimidines  (t1-8) have been undertaken
by the condensation of different 2-methylthio-4-(p-aminophenylsulphonyl-










The constitution of the products (t1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (t1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(t1-8)             R=Aryl
295Studies on pyrimidinyl sulphonamides...






































































































































296Studies on pyrimidinyl sulphonamides...






































   Internal Standard : TMS; Solvent : CDCl3, DMSO; Instrument : BRUKER Spectrom-
   eter (300 MHz)































































































































































































m/z = 414 (M-1)
m/z = 399 (M-2) m/z = 370 (M+2)
m/z = 311 (M+1)
m/z = 342
m/z = 429
m/z = 148 (M-1)
m/z = 291 (M-1) (BP)
m/z = 277 (M-2)
m/z = 158 (M+2)
m/z = 173 (M-1) m/z = 203 (M+2) m/z = 249 (M+1)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-HYDRAZINO-4-
(p -AMINOPHENYLSULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYLPYRI-
MIDINES .
(A) Preparation of 2-methylthio-4-(p-aminophenylsulphonylamino)-5-car -
boxamid o-6-(4’-methoxyphenyl)pyrimidine (r5).
For preparation refer Part-IIB, Section-VIII, Page No. 273.
(B) Preparation of 2-hydrazino-4-(p-aminophenylsulphonylamino)-5-car-
boxamido-6- (4’-methoxyphenyl)pyrimidine (t5).
A mixture of 2-methylthio-4-(p-aminophenylsulphonylamino)-5-
carboxamido-6-(4’-methoxyphenyl)pyrimidine  (4.45, 0.01 M) and hydrazine
hydrate  (1.0 ml, 0.02M) in ethanol (30 ml) was heated under reflux condition for
five hrs. The content was poured into ice cold water and filtered. The product was
isolated and crystallized from methanol:dioxane(1:1) . Yield : 54%, M.P. : 120°C,
Rf
1
 :  0.55,  Rf
2
 :  0.61 (Required :C: 50.35%; H: 4.43%; N: 22.84% for
C18H19N7O4S, Found : C: 50.31%; H: 4.39%; N:22.80% ).
Similarly, other compounds  (t1-8) were synthesized. The physical data
are recorded in Table No. 20.
(C) Antimicrobial activity of 2-hydrazino-4-(p-aminophenylsulphonyl-
amino)-5-carboxamido-6-arylpyrimidines (t1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33. The zone of inhibition of test solution are recorded in Table
No. 20a, 20b & 20c.





































































   
































































































































































































































































































































































































   
   







   
   







68 47 63 66 54 46 50 72
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SECTION - XI
PREPARATION AND BIOLOGICAL SCREENING OF 2-[(2’,4’-DINITRO-
PHENYL)THIO]-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBOXAMIDO- 6-
ARYLPYRIMIDINES .
Keeping in view the interesting properties223-243  and pharmacologi-
cal activities 244-283  of sulphonamides , it has been revealed that sulphonami-
des are valuable drugs for various diseases and for viral diseases. These obser-
vation led us to synthesis of some novel 2-(2’,4’-dinitrophenyl)thio]-4-(p -amino-
phenylsulphonylamino)-5-carboxamido-6-arylpyrimidines  (u1-8) have been
undertaken by the condensation of different 2-[(2’,4’-dinitrophenyl)thio]-4-amino-
5-carboxamido-6-arylpyrimidines with p-acetamidophenylsulphonylchlo-












The constitution of the products (u1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (u1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(u1-8)              R=Aryl
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PMR SPECTRAL STUDY OF 2-[(2’,4’-DINITROPHENYL)THIO]-4-(p-AMINO-














































   Internal Standard : TMS; Solvent : DMSO; Instrument : BRUKER Spectrometer (300
   MHz)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-[(2’,4’-DINITRO-
PHENYL)THIO]-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBOXAMIDO-
6-ARYLPYRIMIDINES .
(A) Preparation of 2-[(2 ’,4 ’-dinitrophenyl)thio]-4-amino-5-cyano-6-(4’’-
methoxyphenyl)-1,6-dihydropyrimidine (VIIe).
For preparation refer Part- IIB, Section - V, Page No. 230.
(B) Preparation of 2-[(2’,4’-dinitrophenyl)thio]-4-amino-5-carboxamido- 6-
(4’’-methoxyphenyl)pyrimidine (XVIIa-h).
A mixture of 2-[(2’,4’-dinitrophenyl)thio]-4-amino-5-cyano-6-aryl-1,6-
dihydropyrimidine (4.26 gm, 0.01 M) was dissolved in conc. sulphuric acid
(20ml) below 5
o
C and kept for 48 hrs. at room temperature. The content was poured
into ice cold water and filtered. The product was isolated and crystallized from etha-





 : 0.70 (Required : C: 48.87%; H: 3.17%; N: 19.00% for C18H14N6O6S,
Found :C: 48.85%; H: 3.13%;N:18.96% ).
Similarly, other compounds  (XVIIa-h) were synthesized. The physical data
are recorded in Table No. 21.
(C) Preparation of 2-[(2’,4’-dinitrophenyl)thio]-4-(p-acetamidophenylsul-
phonylamino)-5-carboxamido-6- (4’’-methoxyphenyl)pyrimidine
(XVIIIa-h ).
A mixture of 2-[(2’,4’-dinitrophenyl)thio]-4-amino-5-carboxamido-6-(4’’-
methoxyphenyl)pyrimidine (4.42 gm, 0.01 M) and p-acetamidophenylsulphonyl-
chloride (2.33 gm, 0.01M) in pyridine (15 ml) was heated under refluxed condition
for 12 hrs. Then the reaction mixture was poured into crushed ice. The product so
obtained was recrystallized from methanol:DMF(1:1). Yield : 40%, M.P. : 205°C,
312Studies on pyrimidinyl sulphonamides...
Rf
1
 :  0.45,  Rf
2
 :  0.65(Required :  C: 48.83%; H: 3.27%; N: 15.34% for
C26H21N7O9S2, Found : C: 48.79%;  H: 3.23%; N:15.30% ).
Similarly, other compounds  (XVIIIa-h) were synthesized. The physical
data are recorded in Table No. 21a.
(D) Preparation of 2-[(2’,4’-dinitrophenyl)thio]-4-(p-aminophenylsulpho-
nylamino)-5-carboxamido-6-(4’’-methoxyphenyl)pyrimidine (u5).
A mixture of 2-[(2’,4’-dinitrophenyl)thio]-4-(p-aminophenylsulpho-
nylamino)-5-carboxamido-6-(4’’-methoxyphenyl)pyrimidine  (6.39 gm, 0.01 M)
and con. HCl (4 ml) in methanol (25 ml) was heated under refluxed condition for
6 hrs. Then the reaction mixture was poured into crushed ice. The  product so
obtained was recrystallized from methanol:DMF(1:2) . Yield : 64%, M.P. : 176°C,
Rf
1
 :  0.49, Rf
2
 :  0.61 (Required :  C: 49.24%; H: 3.18%; N: 16.41% for
C24H19N7O8S2, Found : C: 48.20%;  H: 3.13%; N:16.35% ).
Similarly, other compounds  (u1-8) were synthesized. The physical data
are recorded in Table No. 21b.
(E) Antimicrobial activity of 2-[(2’,4’-dinitrophenyl)thio]-4-(p-aminophenyl-
sulphonylamino)-5-carboxamido-6-arylpyrimidines (u1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33. The zone of inhibition of test solution are recorded in Table
No. 21c, 21d & 21e.

















































































































































































































































































































































































































































































   
   







   
   







58 45 49 61 52 63 70 48




























































































































































































































































































































































































































































































   
   







   
   











































































































   


































































































































































































































































































































































































































   
   







   
   







65 63 71 67 64 58 78 66
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SECTION - XII
PREPARATION AND BIOLOGICAL SCREENING OF 2-[(2’,4’-DINITRO-
PHENYL)SULPHONYL]-4-(p-AMINOPHENYLSULPHONYLAMINO)-5-CARBO-
XAMIDO-6-ARYLPYRIMIDINES .
Keeping in view the interesting properties223-243  and pharmacologi-
cal activities 244-283  of sulphonamides , it has been revealed that sulphonami-
des are valuable drugs for various diseases and for viral diseases. These obser-
vation led us to synthesis of some novel 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-
(p-aminophenylsulphonylamino)-5-carboxamido-6-arylpyrimidines (v1-8 )
have been undertaken by the condensation of different 2-[(2’,4’-dinitrophen-
yl)sulphonyl]-4-amino-5-carboxamido-6-arylpyrimidines  with p-acetami-















The constitution of the products (v1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (v1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
(v1-8)     R=Aryl
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   Internal Standard : TMS; Solvent : CDCl3, DMSO; Instrument : BRUKER Spectrom-
   eter (300 MHz)


































































































































































































































































































m/z = 496 (M+2)
m/z = 474
m/z = 133 (M-1)
m/z = 239 (M+1)
m/z = 431 (M+1)
m/z = 403 (M+1)m/z = 389 (M+1)m/z = 358 m/z = 343 (M
-1)
m/z = 285 (M+1)
m/z = 540(M-1)m/z = 569 (M+2) (BP)m/z = 614 (M+1)
m/z = 77
m/z = 92 (M-1)
m/z = 526 (M -1)
(v5)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 2-[(2’,4’-DINITRO-
PHENYL)SULPHONYL]-4- (p -AMINOPHENYLSULPHONYLAMINO)-5-
CARBOXAMIDO-6-ARYLPYRIMIDINES .
(A) Preparation of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-amino-5-cyano-6-
(4’’-methoxyphenyl)pyrimidine (IX e).
For preparation refer Part- IIB, Section - VI, Page No. 244.
(B) Preparation of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-amino-5-carbox-
amido-6-(4’’-methoxyphenyl)pyrimidine (XIX e).
A mixture of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-amino-5-cyano-6-(4’’-
methoxyphenyl)pyrimidine (4.56 gm, 0.01 M) was dissolved in conc. sulphuric
acid  (20ml) below 5 oC and kept for 48 hrs. at room temperature. The content was
poured into ice cold water and filtered. The product was isolated and crystallized
from methanol:dioxane(1:1) . Yield : 42%, M.P. : 105°C, Rf
1
 : 0.50, Rf
2
 : 0.66
(Required :C: 45.57%; H: 2.95%; N: 17.72% for C18H14N6O8S , Found : C:
45.53%;H: 2.91%; N:17.68% ).
Similarly, other compounds  (XIXa-h) were synthesized. The physical data
are recorded in Table No. 22.
(C) Preparation of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-(p-acetamido-
phenylsulphonylamino)-5-carboxamido-6-(4’’-methoxyphenyl)py-
rimidine (XXa-h).
A mixture of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-amino-5-carboxamido-
-6-(4’’-methoxyphenyl)pyrimidine (4.74 gm, 0.01 M) and p-acetamidophenyl-
sulphonylchloride  (2.33 gm, 0.01M) in pyridine (15 ml) was heated under re-
fluxed condition for 12 hrs. Then the reaction mixture was poured into crushed ice.
The  product  so obtained  was recrystallized from DMF . Yield : 50%, M.P. : 170°C,
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Rf
1
 :  0 .39,  Rf
2
 :  0.52(Required :C: 46.50%; H: 3.13%; N: 14.60% for
C26H21N7O11S2, Found : C: 46.45%;H: 3.09%; N:14.56% ).
Similarly, other compounds  (v1-8) were synthesized. The physical data
are recorded in Table No. 22a.
(D) Preparation of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-(p-aminophenyl-
sulphonylamino)-5-carboxamido-6-(4’’-methoxyphenyl)pyrimidine (u5).
A mixture of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-(p-aminophenylsulph-
onylamino)-5-carboxamido-6-(4’’-methoxyphenyl)pyrimidine  (6.71 gm, 0.01
M) and con.HCl (4 ml) in methanol (25 ml) was heated under refluxed condition
for 6 hrs. Then the reaction mixture was poured into crushed ice. The  product so
obtained was recrystallized from methanol:DMF(1:3) . Yield : 52%, M.P. : 155°C,
Rf
1
 :  0.57,  Rf
2
 :  0.64 (Required :C: 61.45%; H: 5.16%; N: 15.58% for
C24H19N7O10S2, Found : C: 61.40%;H: 5.12%; N:15.52% ).
Similarly, other compounds  (v1-8) were synthesized. The physical data
are recorded in Table No. 22b.
(E) Antimicrobial activity of 2-[(2’,4’-dinitrophenyl)sulphonyl]-4-(p-amino-
phenylsulphonylamino)-5-carboxamido-6-arylpyrimidines (v1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33. The zone of inhibition of test solution are recorded in Table
No. 22c, 22d & 22e.
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PART - III
STUDIES ON 1,4-DIHYDROPYRIDINE DERIVATIVES
INTRODUCTION
In 1,4-dihydropyridine  either imino (NH) or substituted nitrogen atom is
present at one position and hydrogen atom at four position of the six membered
hetrocyclic ring which can be represented as under (82).
  R1, R4  = H / Alkyl / Aryl
                   R2, R6  = Methyl
                                                          R3, R5  =  Acetyl /Carbmethoxy/
                          Carbethoxy / N-Aryl Carbamoyl
1,4-dihydropyridine contribute as an important class of compound in
medicinal  chemistry,  leading to several new drugs currently  widely used especially
as calcium channel antagonist283  and other cardiovascular diseases also.
SYNTHETIC METHODS OF  DIHYDROPYRIDINE
B. Chekavichus et.al.,290 has proposed following kind of successive intermi-

































The synthesis of 1,4-dihydropyridines  involves following steps.
(82)
(A)










(1) Intermediate (A) involves cyclisation of 3-arylaminocrotonate  and arylidene
followed by the rearrangement of hydrogen.
(2) Intermediate (B) involves dehydration of  (A) with loss of equimolar quantity
of water.
(3) Intermediate (C) involves isomerisation of intermediate of (B) and obtained
regio and stereo selective 1,4-dihydropyridine  as a final product .
It has been observed that in the presence of piperidine as a catalyst,
pyran was formed as an intermediate by the cyclocondensation of aliphatic or aro-
matic aldehydes with 1,3-diketones , followed by the dehydration of pyran through
the reaction with aliphatic or aromatic amines affored final product. Formation of

































       R, R3 = H / Aryl / Aryl



































































(1) Abstraction of proton by base from ethyl acetoacetate  form nucleophile.
(2) Attack of nucleophile on aldehyde molecule to yield bis-keto ester .
(3) Condensation of NH3 with bis-keto ester  with removel of water molecule
to give 1,4-dihydropyridine  derivative.
SYNTHETIC METHODS OF  1,4-DIHYDROPYRIDINE
Different synthetic methods for the synthesis of 1,4-dihydropyridine
are as follows.
(1) By the condensation of aromatic or aliphatic aldehydes with acetoacet-
ateester and aromatic / aliphatic amine in presence of pyridine 284-287 .
(2) By the condensation of aliphatic or aromatic aldehydes with 3-amino
crotonate  and 1,3-diketone 288-295 .
(3) By the condensation of arylidine with 3-aminocrotonate296.
(4) By the condensation of aliphatic or aromatic aldehydes with various 1,3-
diketones  in presence of ammonia or ammonium carbonate297-299 .
(5)       By the condensation of a.b  -unsaturated ketones  with malononitrile and
cyanoacetamide300 .
(6)      By the condensation of o-nitrobenzaldehyde, b  -amino butaricacid
and methylpripiolate in gl. acetic acid 301  .
(7) By the knoevenagel condensation of benzaldehyde with acetoaceticester
in presence of b -alanine as catalyst and subsequent cyclocondensation
of theresulting benzylidene with 3-amino crotonate 302  .
(8)      By the regio and chemoselective addition of  Ph2Cu(CN)Li2 to substituted
N-alkylpyridium salts  followed by acylation of the intermediate 303  .
(9)      By the condensation of 1,3-diketones  ,alkyl or aryl aldehydes  with aq.
ammonium hydroxide  in the presence of piperidine or piperidyl acetate
or potassium acetate or potassium carbonate or gla. acetic acid304-306 .
(10)    By the condensation of two moles of thiobarbituric acid , aromatic amines
and aromatic aldehydes307,308 .
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THERAPEUTIC IMPORTANCE OF 1,4-DIHYDROPYRIDINE
The research on 1,4-dihydropyridine  system is of current interest due to
their valuable activities as calcium channel antagonist , vasodilator , cardio-
vascular etc. beside the currently established drugs Nifedipine309,310  ,
Nicardipine311,312   Many dihydropyridine derivatives have been synthesized
world wide313-316 . and have led to numerous second generation commercial
product317-324 . such as Nimodipine325,326 , Nisodipine327 , Nitrendipine328,
Amlodopine329, Felodipine330 , Isradipine331 , Manidipine332 and Nelva-
dipine333 . Some of their compounds are characterized by longer bioactivity of
greater tissue selectivity.  1,4-dihydropyridine derivatives are associated with
diverse biological activities viz.
(a) Antiarythemic 334 (b)   Antiinflammatory335
(c) Antiallergic336 (d) Antiulcer337
(e) Antitumor287 (f) Vasodilator338
(g) Enzymetic 339,340 (h)   Calcium channel antagonist 341-343
(i) Antihypertensive344,345 (j) Antihypolipemic 346
(k) Antimayocardic ischemic 347 (l) Cardiovascular348
(m) Photo induced relaxation291 ,301 (n) Antitubercular agents349
I. Nadeem et.al.,292 (83) have demonstrated the structure function relation-
ship of calcium channel and photo induced relaxation of novel 1,4-dihydropyri-
dines.  Activities of calcium channel antagonists in vitro were detected
and gave such conclusion about structure-activity relationship (SARs).
(1) Relative potency order for C-4 phenyl substituents is ortho and meta is
greater then pera.





  R1=COOCH3 / COOC2H5




G. Charles et.al.,350 (84) have synthesized 1,4-dihydropyridines  for treat-
ment of prostatic hyperplasia .
















Dihydropyridine derivatives (84) have been found to be useful in treai-
ng benign prostate hyperplasia inhibition of cholesterol synthesis (85) show-
ed ‘ki’ of 1.9 m.mol/kg. In reducing urethral pressure in vivo  in dog.
More recently B. M. Khadikar et.al.,351 prepared 1,4-dihydropyridine  deri-
vatives (86) and tested its biological activity.
Out of many 1,4-dihydropyridine  drugs only Flordipine (87)  is N-substi-
tuted derivative that has proved to be very good calcium channel antagonist ,
contrary to be belief proposed by D.J.Triggle 352 that N-substituted 1,4-dihydro-
pyridine was not shown good antihypertensive activity, probably the concept of

























N-methylnimodipine  (88) was found to possess antidepressive 353 char-
acteristics (20 mg.P.O reduce the immobile phase by approximately 22% com-
parison to control values), which provides excellent example of mechanism of
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V. Michael et.al.,354 prepared antihypertensive and coronary vasodi-
lator N-substituted 1,4-dihydropyridine  (89).
A. Daich et.al.,355  prepared calcium antagonist effect of 1,4-dihydro-
pyr idine (90)  and M. Suarez et.al . ,356 prepared calcium antagonist
modulators 1,4-dihydropyridine (91) .

















      R1,R2,R3= methyl / ethyl
      X=O, S, N
M. Sharifzadeh et.al.,357 prepared anticonvulsant 1,4-dihydropyridine (92)










R(CH 2)nCOO COO(CH 2)nR
O2N CH3
R = CH3, CH(CH3)2,C6H5,C(CH3)3,





















M. C. R. Franseen et.al.,359  have synthesized 4-substituted-1,4-dihydro-















=Et / Pr / iPr











A. Takahara et.al.,360  prepared and calcium blockers N-type 1,4-dihy-
dropyridine (95).
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on 1,4-dihydropyridines  for their various methods of synthesis
and different biological activities, synthesis of 1,4-dihydropyridines  have been
under taken which can be summarized in the following sections as under.
SECTION - I   :  PREPARATION AND BIOLOGICAL SCREENING OF 1N-ARYL-2,6-
     DIMETHYL-3,5-DICARBETHOXY-4-(1’N-PHENYL-3’-METHYL-5’-
     CHLOROPYRAZOL-4’-YL)-1,4-DIHYDROPYRIDINES .
SECTION - II  :  PREPARATION AND BIOLOGICAL SCREENING OF 1N-ARYL-2,6-
     DIMETHYL-3,5-DICARBMETHOXY-4-(1’N-PHENYL-3’-METHYL-5’-






PREPARATION AND BIOLOGICAL SCREENING OF 1N-ARYL-2,6-
DIMETHYL-3,5-DICARBETHOXY-4-(1’N-PHENYL-3’-METHYL-5’-CHLORO-
PYRAZOL-4’-YL)-1,4-DIHYDROPYRIDINES .
In view to various biodynamic activities334-349  of 1,4-dihydropyridine
and with a view to have potent therapeutic agents, the synthesis of 1N-aryl-2,6-
dimethyl-3,5-dicarbethoxy-4-(1’N-phenyl-3’-methyl-5’-chloropyrazol-4’-yl)-
1,4-dihydropyridines (w1-8) have been undertaken by the condensation of
1N-phe-nyl-5-chloro-3-methylpyrazol-4-carboxaldehyde  and ethyl acetoac-










The constitution of the products (w1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (w1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized com-
pounds were compared with standard drugs  viz. Ampicillin , Chlorampheni-
col, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).




ReferenceType  Vibration  mode















C=C + C=N and ring
skeletal vibration
C-H  str.























2975  - 2900
2880  - 2860
1460  - 1435
1385  - 1300
1520  - 1480
1580  - 1520
 3080 - 3030
1125  - 1090
840 -  810
1650  - 1580
1220  - 1020
1690  - 1650
1275  - 1200
1075  - 1000




































































































































































































































































































































































m/z = 107 (M-1)





m/z = 281 (M+1)
m/z = 253m/z = 245 (M -2)m/z = 225
m/z = 549.5
m/z = 161 (M-1) m/z = 219 (M+1)
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PREPARATION AND BIOLOGICAL SCREENING OF 1N-ARYL-2,6-DIM-
ETHYL-3,5-DICARBETHOXY-4-(1’N -PHENYL-3’-METHYL-5’-CHLORO-
PYRAZOL-4’-YL)-1,4-DIHYDROPYRIDINES .
(A) Preparation of 1N-phenyl-2,6-dimethyl-3,5-dicarbethoxy-4-(1’N-phe-
nyl-3’-methyl-5’-chloropyrazol-4’-yl)-1,4-dihydropyridine (w1).
A mixture of 1N-phenyl-5-chloro-3-methylpyrazol-4-carboxaldehyde
(2.20 gm, 0.01 M), ethyl aceto acetate  (2.60 ml, 0.02 M) and aniline (0.93 gm,
0.01 M) in ethanol (30 ml) was heated under refluxed condition for 6 hrs. The
content was poured into ice cold water. The separated solid was filtered and crys-
tallized from dioxane:methanol (1:1) . Yield : 70%, M.P. : 192°C, Rf
1
 : 0.55, Rf
2
 :
0.63 (Required :  C: 66.99%; H: 5.77%; N: 8.08% for C29H30N3O4Cl, Found : C:
66.94%; H: 5.73%; N: 8.02% ).
Similarly, other compounds  (w1-8) were synthesized. The physical data
are recorded in Table No. 23.
(B) Antimicrobial activity of 1N-aryl-2,6-dimethyl-3,5-dicarbethoxy-4-
(1’N-phenyl-3’-methyl-5’-chloropyrazol-4’-yl)-1,4-dihydropyridines
(w1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table







































































































































































































































































































































































































































































































   
   







   
   


























































































































































































































































































































































































































































































   










































































































































































































































































































































































































































































































































































































































































































































   

























































































































































































































































































































































































































































































































































































































































































   

















































































































































































































































































PREPARATION AND BIOLOGICAL SCREENING OF 1N-ARYL-2,6-
DIMETHYL-3,5-DICARBMETHOXY-4-(1’N-PHENYL-3’-METHYL-5’-CHLORO-
PYRAZOL-4’-YL)-1,4-DIHYDROPYRIDINES .
In view to various biodynamic activities334-349  of 1,4-dihydropyridine
and with a view to have potent therapeutic agents, the synthesis of 1N-aryl-2,6-
dimethyl-3,5-dicarbmethoxy-4-(1’N-phenyl-3’-methyl-5’-chloropyrazol-4’-yl)-
1,4-dihydropyridines (x1-8)  have been undertaken by the condensation o f
1N-phenyl-5-chloro-3-methylpyrazol-4-carboxaldehyde  and methyl acetoac-












The constitution of the products (x1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (x1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96  and
B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gramnegative)
bacterial strain and antifungal activity towards A. niger  MTCC-282 and
C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (control), 5,
10, 25, 50, 100, 200, 500 . The biological activities of the synthesized compounds
were compared with standard drugs viz. Ampicillin, Chloramphenicol ,
Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifungal).
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C=C + C=N and ring
skeletal vibration
C-H  str.
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m/z = 477.5 (M-1)
m/z = 447.5 (M+1) (BP) m/z = 411
m/z = 77
m/z = 93 (M-1)
m/z = 381
m/z = 134 (M+1)
m/z = 491.5 m/z = 351 (M+2)
m/z = 158 (M-1)
m/z = 323 
m/z = 188
m/z = 215 m/z = 237 (M-2) m/z = 265(M+2)
m/z = 295 (M+2)






































PREPARATION AND BIOLOGICAL SCREENING OF 1N-ARYL-2,6-DIM-
ETHYL-3,5-DICARBMETHOXY-4-(1’N -PHENYL-3’-METHYL-5’-CHLORO
PYRAZOL-4’-YL)-1,4-DIHYDROPYRIDINES .
(A) Preparation of 1N-phenyl-2,6-dimethyl-3,5-dicarbmethoxy-4-(1’N-phe-
nyl-3’-methyl-5’-chloropyrazol-4’-yl)-1,4-dihydropyridine (x1).
A mixture of 1N-phenyl-5-chloro-3-methylpyrazol-4-carboxaldehyde
(2.20 gm, 0.01 M), methyl acetoacetate  (2.26 ml, 0.02 M) and aniline (0.93 gm,
0.01 M) in ethanol (30 ml) was heated under refluxed condition for 6 hrs. The
content was poured into ice cold  water. The separated solid was filtered and





 : 0.57(Required :  C: 65.92%; H: 5.16%; N: 8.54% for C27H26N3O4Cl, Found :
C: 65.77%; H: 5.12%; N: 8.50% ).
Similarly, other compounds  (x1-8) were synthesized. The physical data
are recorded in Table No.24 .
(B) Antimicrobial activity of 1N-aryl-2,6-dimethyl-3,5-dicarbmethoxy-4-
(1’N-phenyl-3’-methyl-5’-chloropyrazol-4’-yl)-1,4-dihydropyridines (x1-8).
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 33 . The zone of inhibition of test solution are recorded in
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    PART - IV
 STUDIES ON PYRIDO[2,3-d;6,5-d ']DIPYRIMIDINES
INTRODUCTION
Pyrido[2,3-d;6,5-d']dipyrimidine  (96) is a fused heterocyclic compound
in which two pyrimidines with their d-position are fused at 2,3 and 6,5 positions of








K.R. Roland et al.,361  have synthesized 4- and 2,4-disubstituted pyrido-
[2,3-d]pyrimidines in 1959. There are other three possible isomers of pyrido-










SYNTHETIC METHOHS OF PYRIDO[2,3-d;6,5-d']DIPYRIMIDINES
Extensive studies have been made in the field of synthesis of pyrido-
[2,3-d]pyrimidines. Various methods have been reported in the literature which
can be described as under. 434,437,439-442
(a) By the cyclocondensation of pyrimidine carboxaldehyde with N -subs-
tituted-2-cyanoacetamide362 .
(b) By the cyclocondensation of 4-aminopyrimidine with ethoxydiethyl-
                          (96)
Pyrido[2,3-d;6,5-d’]dipyrimidine
                        (97)
     Pyrido[3,2-d]pyrimidine
                        (99)
     Pyrido[3,4-d]pyrimidine
                        (98)
     Pyrido[4,3-d]pyrimidine
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methylene malonate led to the formation of 5-oxo-2-(4/3-pyrimidinyl)py-
rido[2,3-d]pyrimidine-6-carboxyllic acid 363 .
(c) By the reaction of 2-(m-nitroaniline)-3-carbethoxypyridine  with N-carbe-
thoxyaminomethane led to formation of pyridopyrimidinediones364 .
(d) By the cyclocondensation of 2-pyridothione derivatives with benzoyliso
thiocyanate or malononitrile led to the formation of pyrido[2,3-d]pyrimi-
dine365.
(e) By the cyclocondensation of 2-amino-pyridine-3-carboxyllic acid  with
urea led to formation of 2,4-dioxo pyrido[2,3-d]pyrimidines366 .
(f) By the hydrolysis of 2-amino-3-cyano-4,6-disubstituted pyridines to 2-
amino-3-carboxamido-4,6-disubstitutedpyridines  followed by the  treat-
ment with aryl isocyanate led to the formation of 3,5,7-trisubstituted
pyrido[2,3-d]pyrimidines367 .
(g) By the cyclization of 3-cyano-1,4-dimethyl-5-ureidomethylene-1H,5H-pyri-
din-2,6-dione  in presence of phosphorous pentoxide led to formation of
pyrido[2,3-d]pyrimidines368 .
(h) By the condensation of 4-amino-2-methoxypyrimidine-5-carboxalde-
hyde with diethyl malonate led to the formation of pyrido[2,3-d]pyrimi-
dines369 .
(i) By the cyclocondensation of 6-amino-2-methoxy-3,4-dihydro-4-pyrimi-
dine with arylidene derivatives of malononitrile led to the formation of
pyrido[2,3-d]pyrimidines370 .
(j) By the reaction of 5-formyl-4-amino-2-oxopyrimidine with ethylcyano-
acetate  led to formation of pyrido[2,3-d]pyrimidines371 .
(k) By the cyclocondensation reaction of aromatic aldehyde with 2 moles
of thiobarbituric acid and aromatic amines372 .
(l) By the cyclocondensation reaction of 6-[(dimethylamino)methylene]amino-
1,3-dimethyluracil  and Benzalacetone led to formation of pyrido[2,3-d ]-
pyrimidines373 .
(m)     By the reaction of 1,3-diaryl-2-thiobarbituric  acid with thiophene-2-car-
baldehyde and aniline led to formation of pyrido[2,3-d]pyrimidines374 .
Pyrido[2,3-d]pyrimidine  have been found to possess remarkable insec-
ticidal375 (100) and herbicidal376 (101) activities.


















R=4-CI-C6H4 / 4-CH3-C6H4     R1=sub. phenyl, R2=H,R4=H / Alkyl, R3=H
Pyrido[2,3-d]pyrimidine derivatives from a class of fused heterocyclic
compound which have interesting pharmacological and biological activities, par-
ticularly the oxo and amino derivatives of pyrido[2,3-d]pyrimidines stand out for
their antitumor377 and antiviral378 activities.
BIOLOGICAL IMPORTANCE OF PYRIDO[2,3-d;6,5-d']DIPYRIMIDINES
The extensive use of pyrido[2,3-d;6,5-d']dipyrimidines  in medicine is due
to its vast biological activities, which are summarized as below.
(a) Antibacterial379-384 (b)      Anticancer385,386
(c)      Diuretic387-391 (d) Anticonvulsant392-394
(e)      Antitumor395-401 (f) Antiallergic agent402,403
(g) Antiphlogistic 404 (h)      CNS depressant405-411
(i)       Antitussive412 (j)       Coronary vasodilator413
(k)      Antihypertensive414-416 (l)       Antiarrythmic agent417
(m)     Immunossuppressing agent418 (n) Antispasmodic 419
(o)      Cardiovascular420 (p)      Antiepileptic 421,422
(q)      Antiprotoxoal423 (r)       Anxiolyticagent424,425
(s)      Antiasthamintics426 (t) Antitubercular427
(u) AntiHIV 428,429
R. F. Meyer et. al.,430  have synthesized  6-aryl-2,7-bis[(trialkylsilyl)amino]
pyrido[2,3-d]pyrimidines (102) and were administered orally to fasting rats at
2 mg/kg and 20 mg/kg and was effective as diuretic .
(100) (101)






S. Minami et. al.,431  have synthesized pyrido[2,3-d]pyrimidines  (103) and
tested for antibacterial ED50  i.p. in mice against pseudomonas aurigenous 6.3
gm and salmonella typhimurium 15.5 mg/kg and an i.v. LD50>500 mg. A. Santilli
et. al.,432 have synthesized 5,6,7,8-tetrahydro-5-oxopyrido[2,3-d]pyrimidines-
6-carbonitrile  (104) and tested as central nervous system depressants  in mice


















R. P. James et. al.,433  have synthesized pyrido[2,3-d]pyrimidines (105)











F. Yoneda et.al.,434  have synthesized Bis(pyridopyrimidines) (106)  as
autorecycling redox catalyst .
     (103)      (104)
     (105)
     (102)




















T. Bear et. al.,435  have synthesized pyrido[2,3-d]pyrimidines (107) as
potent antitumor  agent. C. J. Blankyel et. al.,436  have synthesized 6-arylpyrido
[2,3-d]pyrimidines (108) and found useful as inhibitors of protein tyrosine
kinase  and thus useful in treating atherosclerosis , restenosis , psoriasis as




















V. K. Ahluwalia et.al.,437  have synthesized pyrido[2.3-d;6,5-d’]dipyrimi-
dines (109)  as important role in the biomimetic oxidations as well as antibiotic
and antibacterial.












     (109)
 R1, R2, NR3R4 = H / C1-8alkyl / C2-8alkyl;
 B = Halogen
     (107)      (108)
R1=2-OCH3C6H4, 2/4-CH3C6H4 ;
R2=H, 2-OCH3C6H4, 4-CH3C6H4 ;
R3=2-NO2, 4-CH3
     (106) R = -C4H9, -C8H17, -C12H25;
n = 6,8,10,12
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D. H. Boshelli et. al.,438  have synthesized pyrido[2,3-d]pyrimidines (110),
(111) and found useful in the treatment of cell proliferatives disorders such as
cancer and restenosis . V. K. Ahluwalia et. al.,439  have synthesized pyrimido[4,5-
b]quinolines (112)  as antimicrobial agent.





























P. S. Mohan et. al.,440
 
have synthesized pyrido[2,3-d;6,5-d’]dipyrimidines
(113) as novel antibacterial agents.














P. T. Perumal et. al.,441  have synthesized 9-aryl-3,3,6,6-tetramethyl-
3,4,6,7,9,10-hexahydro-1,8-(2H,5H)acridinedione (114) derivatives.
     (113)
     (111)
     (112)
 R1=R2=H ; R3=H / alkyl ; R4=R5=H ;
 W=NH / S ; X=O / NH
     (110)
 R1=2/3-OCH3C6H4, 2/3/4-CH3C6H4;
 R2=4-CH3C6H4, 2-NO2C6H4
 R = H, 2/4-CH3C6H4,
        2/4-CH3C6H4, 4-ClC6H4
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R. J. Perner et al.,442  have synthesized pyrido[2,3-d]pyrimidines (115)










In view to get potent therapeutic agents, the synthesis of pyrido[2,3-d:6,5-d’]-
dipyrimidine derivatives have been undertaken which can be described as under.








     (115)
     (114)
 Y=H, Cl; X = CH, N
 R1, R2 = H, Cl;
 R3 = OCH3, CH3, OH, Cl
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SECTION - I
PREPARATION AND BIOLOGICAL SCREENING OF 1,2,3,4,6,7,8,9-
OCTAHYDRO-10N-ARYL-5-(1’N-PHENYL-5’-CHLORO-3’-METHYLPYRAZOL-
4’-YL)-2,4,6,8,-TETRAOXO-5H,10H-PYRIDO[2,3-d;6,5-d’]DIPYRIMIDINES .
Due to various biodynamic activities379-429 of pyrido[2,3-d;6,5-d’]-
dipyrimidines  and with a view to have potent therapeutic agents, the synthesis of
1,2,3,4,6,7,8,9-octahydro-10N-aryl-5-(1’N-phenyl-5’-chloro-3’-methylpyrazol-
4’-yl)-2,4,6,8-tetraoxo-5H,10H-pyrido[2,3-d; 6,5-d’]dipyrimidines  (y1 -8 )
434,437,439-442  have been undertaken by the condensation of 1N-phenyl-5-















The constitution of the products (y1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (y1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96  and
B. subtil l is MTCC-441  (Gram posit ive) and E. coli  MTCC-443  (Gram
negative) bacterial strain and antifungal activity towards A. niger  MTCC-282
and C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (con-
trol), 5, 10, 25, 50, 100, 200, 500. The biological activit ies of the synthesized
compounds were compared with standard drugs  viz. Ampicillin , Chloram-
phenicol, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifun-
gal).
(y1-8)                 R=Aryl
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Frequency in cm-1
Observed Reported
ReferenceType  Vibration  mode





































 C-H i.p. def.
 C-H o.o.p. def.
 N-H str. (br)
 C=N str.
 N-N  str.
 C-N str.
 C=O str. (br)
 C-CI str.
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Internal Standard : TMS ; Solvent : DMSO; Instrument : BRUKER Spectrometer (300 MHz)
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+
m/z = 501.5 m/z = 477.5 (M -1)
m/z = 453.5 (M-1) m/z = 431.5
m/z = 415.5
m/z = 365 (M+2)
m/z = 77
m/z = 93 (M-2)
m/z = 105 (M-1)
m/z = 350
m/z = 321 (M-1)
m/z = 297 (M+2)
m/z = 515.5
m/z = 119 (M-2)
m/z = 133 (M-1)
m/z = 162 (M-1)
m/z = 281 (M+1)
m/z = 266 (M -1)m/z = 251 (M-2)m/z = 239 m/z = 229 (M+1)
m/z = 216 (M+1)
m/z = 188 (M+2)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 1,2,3,4,6,7,8,9 -
OCTAHYDRO-10N-ARYL-5-(1’N-PHE NYL-5’-CHLORO-3’-METHYLPYRA-
ZOL-4’-YL)-2,4,6,8,-TETRAOXO-5H,10H-PYRIDO[2,3-d;6,5-d’]DIPYRIMIDIN ES.




A mixture of 1N-phenyl-5-chloro-3-methylpyrazol-4-carboxaldehyde
(2.20 gm, 0.01 M), p-methylaniline (1.07 g, 0.01 M) and barbituric acid  (2.56
gm, 0.02 M) in ethanol (30 ml) was heated under refluxed condition for 6 hrs. The
content was poured into ice cold water. The separated solid was filtered and crys-
tallized from DMF : dioxane  (1:2). Yield : 52%, M.P. : 173°C, R f
1
 : 0.57, R f
2
 : 0.64
(Required :  C: 58.92%; H: 3.78%; N: 18.51% for C26H20N7O4Cl, Found : C:
58.87%; H: 3.74%; N:18.46% ).
Similarly, other compounds  (y1-8) were synthesized. The physical data
are recorded in Table No. 25.
(B) Antimicrobial activity of 1,2,3,4,6,7,8,9-octahydro-10N-aryl-5-(1’N-
phenyl-5’-chloro-3’-methylpyrazol-4’-yl)-2,4,6,8,-tetraoxo-5H,10H-
pyrido[2,3-d;6,5-d’]dipyrimidines (y1-8).
Antimicrobial activity  testing was carried out as described in part-I, sec-
tion-I, page No. 33 . The zone of inhibition of test solution are recorded in Table
No. 25a, 25b & 25c .
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SECTION - II
PREPARATION AND BIOLOGICAL SCREENING OF 1,2,3,4,6,7,8,9-
OCTAHYDRO-10N-ARYL-5-(1’N-PHENYL-5’-CHLORO-3’-METHYLPYRAZOL-
4’-YL)-4,6-DIOXO-2,8-DITHIO-5H,10H-PYRIDO[2,3-d;6,5-d’]DIPYRIMIDINES .
Due to various biodynamic activities379-429  of pyrido[2,3-d;6,5-d’]-
dipyrimidines  and with a view to have potent therapeutic agents, the synthesis of
1,2,3,4,6,7,8,9-octahydro-10N-aryl-5-(1’N-phenyl-5’-chloro-3’-methylpyra-
zol-4’-yl)-4,6-dioxo-2,8-dithio-5H,10H-pyrido[2,3-d;6,5-d’]dipyrimidines (z1-8)
434,437,439-442 have been undertaken by the condensation of 1N-phenyl-5-
chloro-3-methylpyrazol-4-carboxaldehyde  and thiobarbituric acid  with differ-














The constitution of the products (z1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (z1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96  and
B. subtil l is MTCC-441  (Gram posit ive) and E. col i  MTCC-443  (Gram
negative) bacterial strain and antifungal activity towards A. niger  MTCC-282
and C. albicans  MTCC-227 fungii at different concentrations (µg/ml) : 0 (con-
trol), 5, 10, 25, 50, 100, 200, 500. The biological activities  of the synthesized
compounds were compared with standard drugs  viz. Ampicillin , Chloram-
phenicol, Ciprofloxacin , Norfloxacin (antibacterial) and Griseofulvin (antifun-
gal).
(z1-8)                R=Aryl
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Frequency in cm-1
Observed Reported
ReferenceType  Vibration  mode
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PMR SPECTRAL STUDY OF  1,2,3,4,6,7,8,9-OCTAHYDRO-10N-(4’’-METHOXY-
PHENYL)-5-(1’N-PHENYL-5’-CHLORO-3’-METHYLPYRAZOL-4’-YL)-4,6,-



































































Internal Standard : TMS ; Solvent : DMSO; Instrument : BRUKER Spectrometer (300 MHz)








































































































































































































































































m/z = 547.5 (M-1)
m/z = 512 (M+1) (BP)
m/z = 471.5 (M+1)
m/z = 439 (M+1)
m/z = 93 (M -2)
m/z = 77
m/z = 133 (M+1) 
m/z = 561.5
m/z = 397 (M-2)
m/z = 200 (M-1) m/z = 354 (M+1)
m/z = 223 (M-2) m/z = 251 (M+1) m/z = 282 (M+2)
m/z = 312 (M+2)
(z6)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF 1,2,3,4,6,7,8,9-
OCTAHYDRO-10N-ARYL-5-(1’N-PHENYL-5’-CHLORO-3’-METHYL PYRAZOL-
4’-YL)-4,6,-DIOXO-2,8-DITHIO-5H ,10H-PYRIDO[2,3-d;6,5-d’]DIPYRIMIDINES .




A mixture of 1N -phenyl-5-chloro-3-methylpyrazol-4-carboxaldehyde
(2.20g, 0.01 M), p-anisidine  (1.23 g, 0.01 M) and thiobarbituric acid  (2.88 g,
0.02 M) in ethanol (30 ml) was heated under refluxed condition for 6 hrs. The
content was poured into ice cold  water. The separated solid was filtered and
crystallized from DMF : dioxane (1:1) .  Yield : 64%, M.P. : 174°C, Rf
1
 : 0.46, Rf
2
 :
0.52 (Required :  C: 54.03%; H: 3.4 6%; N: 16.97% for C26H20N7O3S2Cl, Found :
C: 53.98%; H: 3.43%; N:16.92% ).
Similarly, other compounds  (z1-8) were synthesized. The physical data
are recorded in Table No. 26.
(B) Antimicrobial activity of 1,2,3,4,6,7,8,9-octahydro-10N-phenyl-5-(1’N-
phenyl-5’-chloro-3’ -methylpyrazol-4’-yl)-4,6,-dioxo-2,8-dithio-5H ,
10H-pyrido[2,3-d;6,5-d’]dipyrimidines (z1-8).
Antimicrobial activity testing was carried out as described in part-I,
section-I, page No. 33 . The zone of inhibition of test solution are recorded in
Table No. 26a, 26b & 26c.
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